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ABSTRACT
Diabetes is a disease characterized by reduced insulin action and secretion, leading
to elevated blood glucose. In the 1990s, studies showed that intravenous injection of
fatty acids led to a sharp negative response in insulin action that subsided hours after
the injection. The molecule associated with diminished insulin signalling response
was a byproduct of fatty acids, diacylglycerol. This dissertation is focused on the
formulation of a model built around the known mechanisms of glucose and fatty acid
storage and metabolism within myocytes, as well as downstream effects of diacylglyc-
erol on insulin action. Data from euglycemic-hyperinsulinemic clamp with fatty acid
infusion studies are used to validate the qualitative behavior of the model and esti-
mate parameters. The model closely matches clinical data and suggests a new metric
to determine quantitative measurements of insulin action downregulation. Analy-
sis and numerical simulation of the long term, piecewise smooth system of ordinary
differential equations demonstrates a discontinuous bifurcation implicating nutrient
excess as a driver of muscular insulin resistance.
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Chapter 1
INTRODUCTION
The prevalence of diabetes has increased significantly in the last 50 years with
type 2 diabetes mellitus (T2DM) accounting for the majority of diabetes cases (CDC,
2013). The pathogenesis of T2DM is understood to be a result of an orchestra of bio-
chemical responses to environmental stimuli, shaped by genetic predisposition (Asso-
ciation et al., 2006). While genetic components have been discovered, the presence
or absence of said genetic components do not turn diabetes on or off, but rather
influence the result of lifestyle behavior. More concisely, diabetes is a disease of afflu-
ence and civilization – showing up wherever American-style diets exist while staying
relatively unseen in communities that eat a more “traditional” diet (Joe, 1994) The
symptoms of diabetes have been known for millenia, characterized by sweet urine
and unquenchable thirst (King and Rubin, 2003). However, the underlying biological
dynamics have only been studied over the last century, as a result of the discovery of
insulin (Banting et al., 1922).
The typical metrics of diabetes recorded include elevated blood sugar, elevated
insulin, and insulin resistance (Association et al., 2006). Adding to the confusion, it
isn’t obvious which of these maladies occurs first (Boden, 1997; Ceriello and Motz,
2004). Elevated blood glucose triggers the pancreas to secrete insulin, and the insulin
then affects the liver, muscles, and fat tissue to consume and utilize the glucose, re-
moving it from the blood. In a healthy human, this process occurs after each meal
and is well regulated in the body (Saltiel and Kahn, 2001). Things take a turn for
the worse, however, when insulin is unable to do its job - this is where the insulin
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resistance comes in. When insulin is ignored by the tissues it targets, the blood
glucose is not consumed and concentrations remain high (Shulman, 2000). The con-
sistently high blood glucose levels force the pancreas to generate and release ever
more insulin, eventually leading to β cell dysfunction. So insulin resistance is the
key that unlocks the path towards diabetes. Additionally, it seems that insulin resis-
tance may not be the direct effect of elevated insulin or glucose, but a response to
excess nutrient consumption and excess fat consumption (Muoio and Newgard, 2008).
Studies in the late 1990’s discovered that lipid content within muscle cells were
correlated with insulin resistance (Perseghin et al., 1999). Further studies showed
that intravenous injection of fatty acids led to a sharp negative response in insulin
action that subsided hours after the injection (Boden et al., 2004, 2001; Roden et al.,
1996). When patients were fed a high-fat diet for 1-week, a 50% increase in IMCL was
seen (Schrauwen-Hinderling et al., 2005). Finally, adipose tissue in the body elevates
plasma free fatty acid concentrations and is linked to elevated IMCL (Capurso and
Capurso, 2012). Taken together, this implicates dietary choices and visceral adipoc-
ity as strong contenders for the cause of insulin resistance. The insulin receptor
(IR) in the muscle cells shed light on the biological reason behind the result – the
insulin receptor substrate (IRS) was serine phosphorylated on a particular residue
which turned the molecule off. When fatty acids accumulate in muscles, a byproduct
called diacylglycerol (DAG) is produced and accumulates in the muscle cell mem-
brane which allows PKC-θ to become activated and serine phosphorylate the IRS
(Yu et al., 2002). The molecule, DAG, is required for many cellular operations, but
when fatty acid concentrations are elevated, the concentration of activated DAG in-
creases (Krebs and Roden, 2005). Additionally, there are other fatty acid byproducts
such as ceramides that result in a similar outcome in vitro, but not necessarily in vivo
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(Krebs and Roden, 2005).
Chronic insulin resistance is of more importance, however. The acute affect of
a high fat meal subsides 12 hours after ingestion (Weintraub et al., 1987), whereas
most people eat meals more frequently. There are multiple hypotheses regarding the
long term generation of IMCL induced insulin resistance. One hypothesis is that fat
in the blood stream is elevated in overweight and obese individuals due to elevated
visceral fat stores which increases the base fatty acid concentration in the blood by
releasing non-esterified fatty acids into the portal vein (Klein, 2004). However, other
studies have shown that subcutaneous fat and IMCL content independently predict
insulin resistance when visceral fat is controlled for, where IMCL concentration has
the strongest predictive power (Goodpaster et al., 1997). Hence there may be a com-
mon cause for both IMCL level and visceral fat stores.
Ingestion of sucrose is suggested to be a cause of visceral fat accumulation (Mat-
suzawa et al., 1995). Direct evidence of sucrose on IMCL accumulation hasn’t been
studied. However, sucrose significantly elevates plasma lipids when compared to an
equi-caloric diet with starch in place of sucrose(Reiser et al., 1979) and elevated
plasma fatty acid availability is the suggested mechanism behind IMCL accumula-
tion. Overconsumption of fructose (a subunit of sucrose) is additionally correlated to
elevated plasma lipids and hepatic insulin resistance (Leˆ et al., 2009). Additionally,
mouse studies suggest that visceral fat and insulin resistance are indissociable under
high-fat feeding trials (Kim et al., 2000). However, it was noted that neither visceral
fat nor insulin resistance increased when the calories from the high-fat diets were
restricted. Hence, excessive calorie consumption may be a necessary condition for
insulin resistance. Additionally, insulin sensitive patients with elevated IMCL levels
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exhibit elevated lipid oxidation (Perseghin et al., 2002). This is also substantiated
by athlete studies that indicate endurance trained athletes have high IMCL levels
with accompanying high oxidation (Goodpaster et al., 2001). Finally, some propose
that mitochondrial dysfunction is a root cause of IMCL accumulation (Kelley et al.,
2002) due to post-hoc measurements, but this view is contested in rat studies that
concurrently show insulin resistance and an increase in mitochondrial quantity and
activity during high fat feeding (Hancock et al., 2008).
Taken together, it seems that elevated fat or fructose (or sucrose) intake at an
excess of daily caloric requirements is sufficient for IMCL accumulation. Since fatty
acids take hours (∼12) to be utilized and cleared from the blood stream after a meal,
it is not unreasonable to assume that the compounding effect of eating three or more
higher fat and calorie meals per day disallows the body to ever reach basal levels of
plasma lipid concentrations. So the muscles are constantly encountering higher FFA
levels, inflating IMCL concentrations and keeping the IRS turned off. Additionally,
inflammatory pathways have been shown to incite insulin resistance (De Luca and
Olefsky, 2008)
Glucose is shuttled into muscle cells primarily by glucose transporters (GluT4)
that are mobilized and activated when insulin binds to insulin receptors on the mem-
brane of muscle cells. So if the IRS is shut off or insufficiently expressed, GluT4
is not sent to the cell membrane to take in glucose. Increases in IMCL have a di-
rect pathway to disabling the IRS, but inflammatory markers are causally related to
decreased IRS activity or expression (De Luca and Olefsky, 2008; Saghizadeh et al.,
1996). A particularly common inflammatory marker, TNF-α, is expressed at elevated
levels in muscles of patients with insulin resistance (Saghizadeh et al., 1996). The
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elevated TNF-α appears to induce serine phosphorylation of the IRS (Hotamisligil
et al., 1996). Additionally, a mouse model attenuated the affect of high-fat feeding
by replacing 6% of fat intake by omega-3 rich fish oil (Storlien et al., 1987). This
is relevant because omega-3 fatty acids are anti-inflammatory in both human and
animal trials (Simopoulos, 2002), whereas other fatty acids may be pro-inflammatory
(Simopoulos, 2002).
The current biological understanding of these cellular dynamics is at the point
that models can be formulated to study caricatures of the cellular environment. The
molecular kinetics and pathways are complete enough to generate mathematical mod-
els based on observed mechanisms. With such models, in silico experiments can be
conducted to validate the model and ultimately elucidate potential emergent dynam-
ics. The confusion surrounding what people believe to be the “optimal human diet”
and the observed increase in diabetes rates across the world is enough to motivate
such studies.
1.1 Biological Background
1.1.1 Cellular Metabolism of Glucose and Fatty Acids
Mitochondria in muscles oxidize glucose and fatty acids to produce adenosine
triphosphate (ATP) (Alberts et al., 2008). Glucose is derived from dietary carbo-
hydrate sources directly, or by hepatic gluconeogenesis. The body stores glucose
in muscles and in the liver as glycogen which can be quickly converted back into
glucose-6-phosphate when necessary for ATP production. Glycogen in the liver can
be converted back into glucose and released into the bloodstream in response to in-
sulin levels (Sindelar et al., 1998). Glycogen in the muscles, however, is converted to
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glucose-6-phosphate to be metabolized when extracellular sources of glucose are low
or during exercise; glycogen in muscles cannot be reconverted to glucose or released
back into the bloodstream (Van Schaftingen and Gerin, 2002). The liver also con-
verts proteins into glucose through the gluconeogenesis pathway, which becomes the
dominant source of hepatic glucose secretion when liver glycogen is depleted (Tirone
and Brunicardi, 2001).
Figure 1.1: Overview of Intramuscular Metabolic and Regulatory Pathways
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Glucose in the blood needs pores through which to enter muscle and liver cells
(among many others) which are opened through a signal cascade in the cell triggered
by insulin binding to receptor on the cell membrane. Insulin is a peptide hormone
that binds to receptors on many cells to generate behavioral changes. In most situa-
tions, insulin’s main role is to stimulate the process of glucose uptake and utilization.
However, when insulin binds to hepatocytes in the liver, the result is a reduction
in liver mediated glucose generation and release in conjunction with an increase in
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glucose storage as glycogen. Adipose tissue responds to insulin by slowing down fatty
acid release and elevating fat storage as triglycerides. Muscles respond to insulin by
storing glucose as glycogen and oxidizing glucose to create energy.
Throughout the pancreas, there are clusters of cells called Islets of Langerhans that
contain a variety of cells. The most important are the α and β cells that produce
glucagon and insulin, respectively. The β cells constantly release slow, oscillatory
bursts of insulin (Simon and Brandenberger, 2002). But when glucose concentrations
in the blood rise, the cells secrete large quantities of insulin (Rorsman and Renstro¨m,
2003).
Muscles have insulin receptors to which insulin binds that aggregate on the cell
membrane, leading to downstream pathways that enable glucose transport into the
cells. The insulin receptors activate themselves when insulin binds by auto-phosphory-
lating their tyrosine residues. Then the insulin receptor substrate (IRS) binds and be-
comes active, attracting a multitude of other molecules to begin various downstream
signals. One of these pathways tells the cell to shuttle glucose transporters (GluT4)
to the cell membrane so glucose can be taken up from the bloodstream.
Glucose inside the cell is modified and converted into glucose-6-phosphate (G6P)
which either gets converted and stored as glycogen or is sent down the metabolic path-
way. The G6P molecules destined to be oxidized in the mitochondria are converted
to pyruvate. Pyruvate is either converted to lactic acid for rapid energy production
during high intensity exercise, or shuttled into the mitochondria where it is converted
into Acetyl-Coenzyme A (A-CoA). The A-CoA enters the krebs cycle which iteratively
generates Adenosine triphosphate (ATP) that the muscle uses for energy dependent
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activities. Acetyl CoA also can be converted by A-CoA Carboxylase (ACC) to be-
come Malonyl CoA, an important molecule in regulating fatty acid metabolism.
Fatty acids, on the other hand, do not require insulin action to enter muscle cells.
As fatty acids are hydrophobic molecules, they can passively diffuse across cellular
membranes. There are fatty acid transporters, but mice studies that knock out the
gene that codes for these transporters demonstrates that they contribute little to fatty
acid infusion under normal conditions. The intracellular fatty acids are lengthened
to long chain fatty acids (LCFA) and either stored or converted for other use. When
fatty acids are stored, they are converted to triglycerides which consist of three fatty
acid tails combined with a glycerol head. Triglycerides in the muscle are called in-
tramyocellular triglycerides (ImcTG) and other intramuscular fatty acids are called
intramyocellular lipids (ImcL).
Some of the LCFAs interact with a catalyst on the mitochondrial membrane called
the carnitine palmitoyltransferase (CPT), which adds a carnitine molecule to the
LCFA allowing it to pass through the mitochondrial membranes. Inside the mito-
chondria, the carnitine is cleaved off and shuttled back out of the mitochondria while
the LCFA is converted to A-CoA. From this point, the A-CoA undergoes the same
process as in glucose metabolism.
The fatty acid transfer process into the mitochondria is regulated by M-CoA. Mal-
onyl CoA deactivates CPT, so LCFAs cannot acquire the carnitine “ticket” into the
mitochondria. This effectively forces the LCFAs to be stored or converted into other
cellular molecules. One of the more important molecules in the context of ImcTG dy-
namics and insulin resistance is Diacylglycerol (DAG), a fatty acid derived molecule
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that resides in the cell membrane.
1.1.2 Intramyocellular Triglyceride and Insulin Resistance
Fatty acids take on multiple forms, namely they can be coarsely divided into sat-
urated and unsaturated categories. While there is nuance in how different kinds of
saturated and unsaturated fatty acids interact, the general distinction is adequate for
this discussion. Fats are utilized in the body in a number of meaningful and necessary
ways, including the production and maintenance of cellular membranes. Every cell
has a phospholipid bilayer that protects the cell and allows for an intracellular envi-
ronment specific to the various molecular interactions cells need to perform. This cell
membrane is a fluid mosaic of phospholipids of various kinds along with cholesterol
and a host of membrane bound proteins. Fatty acids in the cell are converted into
phospholipids through a variety of pathways depending on the resultant phospholipid.
One particular variety of phospholipid is a phosphoinositide, which is a structure
with a two strand fatty acid tail with an inositol sugar head. The phosphatidylinosi-
tol 4,5-bisphosphate (PI(4,5)P2) is a chemically active phospholipid involved in many
signalling pathways, usually involving G-protein coupled receptors. When PI(4,5)P2
is activated, the inositol sugar head is cleaved off releasing inositol 1,4,5 trisphos-
phate (IP3), which goes on through the cytoplasm to affect downstream pathways
(Alberts et al., 2008). However, the key point is that the fatty acid tail is left in the
cell membrane which is now called diacylglycerol (DAG). Additionally, when fatty
acids are labeled upon ingestion and tracked, unsaturated FA are readily converted
into triglyceride whereas saturated FA are converted to phospholipids, some of which
allow DAG accumulation (Montell et al., 2001).
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The membrane bound DAG is physiologically active, and binds to various forms
of protein kinase C (PKC). When PKC binds to DAG, the PKC molecule can be
activated by calcium ions. The activated PKC molecule is a serine/threonine ac-
tivating molecule, and is namely responsible for serine phosphorylating the insulin
receptor substrate (IRS), effectively shutting off the downstream insulin signal (Yu
et al., 2002). Hence, an accumulation of DAG in the cell membrane allows rapid
and constant PKC activation, which in turn regulates IRS activation and mutes the
insulin signals pathway.
Another phospholipid of note is sphingomyelin. This molecule begins production
in the endoplasmic reticulum (ER) where ceramide is constructed by combining fatty
acids with serine. The ER then exports the ceramide into the golgi apparatus where
it is given a phosphocholine head to form the final sphingomyelin (Alberts et al.,
2008). Again, availability of long chain saturated fatty acids that allow for the start
of ceramide synthesis (Summers, 2006), whereas fatty acids incorporated later in the
production of ceramide can be either saturated or unsaturated. The mechanism by
which ceramide accumulation affects insulin signalling is not clearly understood and
could be due to one of multiple potential interruptions in the insulin signalling path-
way (Summers, 2006). Some argue that ceramide is independently sufficient for IMCL
mediated insulin resistance (Chavez et al., 2003), but since the main mechanism is
still under debate, this research will focus on modeling DAG mediated IRS disruption.
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1.2 Previous Mathematical Work
Mathematical models have been used to understand biological dynamics since at
least the late 18th century, with population growth described by Malthus (Malthus,
1798), resource constrained population growth by Verhulst (Verhulst, 1838) (and
subsequently Pearl and Reed (Pearl and Reed, 1920)), and multi-species competi-
tion models by Lotka and Volterra (Lotka, 1925; Volterra, 1928). The universe of
mathematical biology extends into many subdivisions including epidemiology (Ross,
1911; Kermack and McKendrick, 1927; Brauer et al., 2001), oncology (Wheldon,
1988; Kuang et al., 2016), ecology (Pielou et al., 1969; Levin et al., 2012), bacte-
rial growth and competition (Smith and Waltman, 1995), diabetes (Makroglou et al.,
2006; Bergman et al., 1979), and chemical kinetics (Michaelis and Menten, 1913;
Hill, 1910) to name only a handful. In the field of cell biology and cell signaling,
mathematical models are used to extend what is already known about the cellular
dynamics, and simulate details not easily attainable via experiment (Aldridge et al.,
2006). Moreover, the theory of metabolic control analysis applies models to describe
elasticity of metabolite flux to enzyme activity in metabolic networks (Heinrich and
Rapoport, 1974; Fell, 1992), i.e. what the fractional change in a metabolic variable
is in response to a fractional change in a parameter (Fell, 1992). The mathematical
tools used in metabolic control analysis are important to test the assumed underlying
metabolic pathways, but they do not explore the time dependent changes in chemical
concentrations as do the tools used in chemical kinetics.
The intracellular kinetics of can be modelled with ordinary differential equations
of the general form
dC
dt
= (generation)− (consumption)
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where the generation and consumption terms can be constant, linear, or non-linear
terms such as Michaelis-Menten interactions (Eungdamrong and Iyengar, 2004). Con-
stant terms represent a concentration independent interaction, such as a continual
drip of bacteria into a chemostat (Smith and Thieme, 2013). An example of such an
interaction in a cell might be diffusion of molecule through a semi-porous membrane,
such as glucose through a fixed number of transporters on a cell membrane. Linear
terms often represent concentration dependent birth or death rates, assuming that
these events occur with exponentially distributed waiting times. However, it’s the
nonlinear dynamics that make these intracellular kinetics interesting.
A common class of cellular kinetics are enzyme dynamics which are commonly
modeled with Michaelis-Menten equations (Cornish-Bowden and Cornish-Bowden,
2012). A simple unidirectional enzymatic interaction might be written as
A+ E
k
⇀ E +B
where substrate A binds to enzyme E and becomes substrate B at rate k. However,
this skips an intermediate step where the substrate A is bound to the enzyme for a
period of time
A+ E
k1⇀ AE
k2⇀ B + E
where E is the free enzyme and AE is the bound substrate and enzyme pair. Then
a system of equations can be constructed to model the interaction
d[A]
dt
= −k1[A][E]
d[E]
dt
= −k1[A][E] + k2[AE]
d[AE]
dt
= k1[A][E]− k2[AE]
d[B]
dt
= k2[AE]
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where [·] indicates the concentration. If we call [Et] = [E] + [AE] the fixed total
bound and unbound enzyme, then we can reduce the system to
d[A]
dt
= −k1[A][Et] + k1[AE]
d[AE]
dt
= k1[A][Et]− (k2 + k1[A])[AE]
d[B]
dt
= k2[AE]
If we assume that [A] >> [Et], then we can assume a quasi-steady state for [AE].
Then [AE]′ = 0, so we can solve for [AE]
[AE] =
[Et][A]
k2
k1
+ [A]
.
If we set vmax = k2[Et] and KM =
k2
k1
then
d[B]
dt
=
vmax[A]
KM + [A]
where KM is called the Michaelis-Menten constant. As many intracellular interactions
are dependent on enzymes, these functional forms are commonly used to model such
dynamics. However, there are shortcomings to this quasi-steady state approximation
when the low enzyme concentration assumption is not met (Pedersen et al., 2008)
and a more robust approximation may be appropriate (i.e. tQSSA (Borghans et al.,
1996)). Additionally, in the case of competition between multiple substrates (say A
and I) and an enzyme, a modified form of the Michaelis-Menten approximation is
used (Yung-Chi and Prusoff, 1973)
vmax[A]
KM
(
1 + [I]
KI
)
+ [A]
where I inhibits the binding of A to E. Depending on the complexity of enzyme and
inhibitor interactions, various forms of Michaelis-Menten approximations are appro-
13
priate.
Exact modeling of intracellular dynamics is weighty and the number of equations
required to capture each interaction between each important molecule makes for very
complicated systems of equations. For example, a mathematical model for sphin-
golipid metabolism in yeast cells required a 63 variable system of equations with even
more parameters (Alvarez-Vasquez et al., 2005). The numerical results validated the
model and in silico experiments allowed testable predictions about the cellular re-
sponse in circumstances that could not be tested experimentally. However, due to
the unwieldy nature of this “kitchen sink” approach to modeling, it is unlikely to
be as useful for cellular dynamics we are less certain about. With this in mind, a
simplistic model that is built on the more important verified cellular dynamics is the
focus of this research.
Furthermore, the biochemical switching that occurs in regulated cellular path-
ways brings about a need to consider piecewise smooth differential equations (PWS).
A PWS system is defined as a system with disjoint domains on which distinct smooth
functions define the dynamics of the system, note that the vector field need not be con-
tinuous on the boundaries between domains (such as in Filippov systems (Di Bernardo
et al., 2008)). Various aspects of PWS systems have been studied, mainly with re-
spect to their applications in mechanical or electrical systems (Bernardo et al., 2008;
Leine and Nijmeijer, 2013). However, the method has been implemented to indi-
cate enzymatic switching in yeast (Simpson et al., 2009), and the basic framework
on which molecular interactions can be modeled by PWS smooth systems have been
discussed (Noel et al., 2010). However, difficulty in such systems arise when cate-
gorizing bifurcations, as PWS systems exhibit bifurcation types that are unseen in
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smooth dynamical systems.
Piecewise smooth differential equations are typically described by
x˙ = Fi(x, ρ;h(x, ρ)), i = 1, 2, . . . ,m
where x = (x1, x2, . . . , xn) is the n-dimensional state variable, ρ is the parameter set,
Fi is the function definition of the system on the interior of each of m domains Ri
(i = 1, 2, . . . ,m), and h(x, ρ) is the switching condition. The boundary that separates
the domains, Ri, is the set Σ = {x|h(x, ρ) = 0}, called the switching manifold. For
example, a simple example in R is
x˙ = −sign(x)
where h(x) = x, F1 = −1 (x > 0), F2 ∈ [−1, 1] (x = 0), and F3 = 1 (x < 0). The
dynamics on the interior of R1 (x > 0) and R2 (x < 0) are simple and easily un-
derstood. However, complications arise when attempting to understand dynamics on
the switching manifold. Systems of this type exhibit border-collision, grazing, sliding,
discontinuous, and discontinuity-induced bifurcations (Bernardo et al., 2008) among
others. Often, these bifurcations occur when interior bifurcations pass through or
touch the switching manifold. However, research in this field has a lot of open prob-
lems concerning specific classes of bifurcations (Colombo et al., 2012).
Full body compartment modelling of glucose-insulin interactions have been stud-
ied and used in clinical settings since at least the 1960s (Bolie, 1961). However, the
nonlinear model introduced by Bergman et al. (1979) which became known as the
“minimal model” was used to define an insulin sensitivity index for frequently sam-
pled intravenous glucose tolerance tests that was vetted against other clinical methods
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of insulin sensitivity determination (Bergman et al., 1987; Welch et al., 1990). The
minimal model was used to create a computational program, MINMOD (Pacini and
Bergman, 1986), that determines an insulin sensitivity index from patient data. This
began a common trend of using models to determine and compare insulin sensitivity,
but others have developed and tested alternative measures of insulin sensitivity to
the gold standard, the euglycemic hyperinsulinemic clamp (Gutt et al., 2000). For
example, the homeostasis model assessment (HOMA) was developed from work by
Turner et al. (1979), which became a standard for measuring insulin resistance and
β-cell function (Matthews et al., 1985). However, the HOMA estimates are insuf-
ficiently precise, and more complicated mathematical models with one or multiple
delays provided improvements over the minimal model (Makroglou et al., 2006). For
instance, Shi et al. (2017), used a system of delayed differential equations to deter-
mine an insulin sensitivity index that improved the results over those obtained by the
minimal model.
The system of delay, integro-differential equations in De Gaetano and Arino (2000)
provided means to improve the insulin release model by requiring insulin release to
depend on the concentration of glucose present in the blood over a past interval of
time. This system was further improved by Li et al. (2001), in which the distributed
delay was weighted over the past time interval. This modification resulted in the
presence of oscillatory solutions, a characteristic of in vivo insulin release that was
not captured in (De Gaetano and Arino, 2000). Additionally, multiple delay models
(Li et al., 2006, 2012) simulating ultradian oscillations were developed and analyzed
the further the mathematical understanding of the glucose-insulin dynamics. These,
coupled with partial differential equations Wach et al. (1995); Mosekilde et al. (1989);
Søeborg et al. (2009) modeling subcutaneous insulin injection site diffusion (simplified
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as ODEs in (Li and Kuang, 2009)) allow for a path toward developing model-based
closed-loop control algorithms for the implementation of an artificial pancreas (Huang
et al., 2012).
The cellular level dynamics of insulin granule release have been studied by Bertuzzi
et al. (2007) with a piecewise smooth continuous system of ordinary differential equa-
tions. Additionally, a cell population model of insulin release were studied by Palumbo
and De Gaetano (2010). It is in these types of mathematical models that we draw
inspiration in developing a mathematical tool for understanding the relation between
intramyocellular lipids and insulin resistance in muscles. As mathematical tools have
proven to be useful in other ways within diabetes research (Nyman et al., 2012), we
seek to advance the understanding of skeletal muscle insulin resistance.
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Chapter 2
MODEL FORMULATION
The key component of this research would be the construction and vetting of a
basic model of IMCL dynamics. Thus the main concern discussed in this proposal
will be on the conversion of biological dynamics to ordinary differential equations.
Moreover, the inherent complexity of biological dynamics requires a strong set of as-
sumptions to move the model formation forward.
2.0.1 Assumptions
The environment of in the models will be considered the “average” muscle cell
across all muscles in the body. This includes smooth and striated muscles, those that
are voluntary and involuntary, but other tissues such as fat tissue or organ tissue will
not be considered in this average. It is known muscles in various parts of the body
metabolize nutrients at different rates and quantities, so this assumption allows for
general picture without concern about how a specific muscle in a specific person is
known to perform. Thus, model variables such as those for glucose or fatty acids only
count the average concentration of said molecule over all the muscles and ignore the
blood concentration levels.
Molecules in muscle cells interact as if we are considering homogeneous ideal gas
dynamics. The viscosity of cellular cytoplasm and the inevitable interference of or-
ganelles and other cellular obstructions are ignored. This assumption is only consid-
ered since the muscle cell studied is the abstract “average” and variations in cell size,
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shape, and configuration are wide enough to ignore specific cellular configurations
and their affect on molecule mobility.
Fatty acids diffuse into muscle cells at a rate proportional to some plasma con-
centration. There is evidence that fatty acids diffuse passively as well as actively into
muscles. However, when the active FFA transport is knocked out in mice studies,
fat still enters the muscle cells at nearly the same rate. Thus for simplification, we
assume that the transport is passive.
The mitochondrial metabolism of fatty acids and glucose occur at rates propor-
tional to intracellular concentrations. Models of mitochondrial activity become com-
plicated fast due to the complicated nature of the ATP (energy) production cycle
(Krebs Cycle) and intricate shuttling of molecules into and out of the dual mitochon-
drial membrane. We keep track of the concentration of unmetabilized A-CoA that is
released and converted into malonyl-CoA.
2.1 Model Construction
We consider a five compartment system of ODEs to model the dynamics between
intramyocellular glucose (G), fatty acid (F ), glycogen (Y ), DAG (D), and M-CoA
(M) concentrations. We consider blood concentrations of glucose and fatty acids
constant and then assume that both diffuse into the muscle cell at a constant rate
(Gin and Fin, respectively). This is a reasonable assumption during euglycemic-
hyperinsulinemic clamp with fatty acid infusion.
The intramyocellular fatty acids and glucose are consumed by the mitochondria
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Figure 2.1: Reduced Pathway to Guide Model Formation
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subject to a pair saturable concentration dependent functions. The rate of fatty
acid metabolism is negatively affected by both glucose and mitochondria byproduct
concentrations. Glucose and fatty acids compete as substrate for the Krebs Cy-
cle, so there is an inherent maximum capacity that the mitochondria can handle.
Finally, malonyl-CoA shuts off CPT-1 (Carnitine palmitoyltransferase I) which in
turn down regulates a necessary pathway to shuttle fatty acids into the mitochon-
dria for catabolism. Glucose is metabolized at a rate governed by saturable function
f1(F,G,M) which is negatively affected by substrate competition with fatty acids.
Fatty acids are metabolized at a rate governed by saturable function f2(F,G,M).
The availability of IMCL to be metabolized is reduced by elevated M-CoA concen-
tration.
Glucose concentration is regulated by conversion to glycogen with general function
f3(G,M). Glycogen can absorb a substantial amount of glucose, and is necessary to
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consider since the glucose infusion is high and constant in euglycemic clamp condi-
tions. In the case of low glucose concentrations, glycogen is broken down to be used
for energy production. Glycogenolysis converts glycogen to glucose-6-phosphate, but
for simplicity we consider this molecule as part of the glucose compartment, G. In
the case of clamped fatty acid infusions, glucose is constantly supplied, so little or no
glycogen is likely to be converted back into G6P for metabolism.
The fatty acid pool is converted to DAG according to the function f4(F,D). Then
DAG is removed from the system by deactivation or conversion to a downstream
molecule at rate µ. Diacylglycerol activates PKC-Θ which leads to inactivation of the
IRS by serine phosphorylating a particular residue, so we reduce the glucose inflow
of glucose by 0 < f5(D) ≤ 1 to simulate insulin resistance.
Figure 2.2: Model Flow Chart
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Finally, M-CoA is created at a rate directly proportional to the metabolism of
21
glucose and fatty acids. The concentration of M decays at rate r.
G˙ = Ginf5(D)−Gf1(G,F,M)− f3(G, Y )
Y˙ = f3(G, Y )
F˙ = Fin − Ff2(G,F,M)− f4(F,D) (2.1)
D˙ = cf4(F,D)− µD
M˙ = aGf1(G,F,M) + bFf2(G,F,M)− rM
2.1.1 Short-term Model: Function Selection
The functions that describe interactions within the model could take many forms.
However, certain key considerations are required by biology. The sub-functions drive
the dynamics within the muscle cells, and a “correct” choice of function cannot be
known until more biological work is conducted. However, validation that certain
functional forms replicate the dynamics that we see in clinical trials numerically can
give a sense of accuracy. Thus, functional forms will be suggested here and tested
numerically against data.
Glucose and Fatty Acid Metabolism, (f1 and f2)
Both glucose and fatty acids are metabolized in the mitochondria after being con-
verted to Acetyl-CoA. Glucose undergoes a conversion to Glucose-6-phosphate and
then into pyruvate before being shuttled into the mitochondria. Therefore, we only
wish to consider the proportion of glucose in a muscle cell that has been converted
in pyruvate for metabolism. Similarly, fatty acids need to be tagged with a carnitine
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molecule in order to be shuttled into the mitochondria. The CPT1 complex attaches
the carnitine to the FA which is removed once the complex is in the mitochondria,
and the carnitine then diffuses back out into the cytoplasm. However, CPT1 is shut
off by Malonyl-CoA which is a byproduct of metabolism. This works as a regulatory
factor to keep FA from being metabolized if the cell has enough energy. Finally, the
mitochondria can only process so much A-CoA at a given time and both glucose and
fatty acids are converted to the same molecule for processing, so there is competition
for substrate.
The biological understanding of mitochondrial metabolism then allows a few
rules about the functional forms of f1 and f2 to be constructed. Only a propor-
tion of the total concentration of glucose (pg) and fatty acids (pf ) are available
for metabolism. There is a saturable rate of oxidation for glucose and fatty acids:
f1 ≤ mg, f2 ≤ mf . Metabolism of one molecule inhibits metabolism of the other
by substrate competition: ∂
∂F
(f1) < 0,
∂
∂G
(f2) < 0. Malonyl-CoA concentration re-
duces the availability of fatty acids to be metabolized, and thus increases glucose
metabolism: ∂
∂M
(f1) > 0,
∂
∂M
(f2) < 0. As glucose or fatty acids increase in con-
centration, the metabolism rates increase monotonically: f1(G + , ·) − f1(G, ·) > 0,
f2(F + , ·)− f2(F, ·) > 0. The metabolism functions are non-negative: f1, f2 ≥ 0.
For our initial numerical simulations, we use a simple functional form that satisfies
the above requirements:
f1 =
mgpgG
k + pgG+ e−qMpfF
f2 =
mfpfF
k + pgG+ e−qMpfF
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where e−qM is the reduction of available fatty acids for metabolism.
Glycogen regulation, f3
Glycogen is produced in an alternate pathway to glucose oxidation from glucose-6-
phosphate. When glycogenesis is enabled, such as during times of elevated plasma
insulin, G-6-P is converted into glycogen for quick energy storage. When glucose
concentration in the muscle cells are lower, glycogen is converted via glycogenolysis
back into G-6-P, then into pyruvate and metabolism begins. To avoid a futile cycle,
insulin action down regulates glycogenolysis so glycogen remains stored for later use.
Then ∂
∂G
(f3) ≥ 0 and ∂∂Y (f3) = 0 is assumed to avoid a futile cycle. Thus we assume
that there is a rate of glucose conversion to glycogen that is saturable with rate p.
Additionally, once glycogen is stored, it doesn’t leave the compartment since insulin
levels remain high.
Then we choose the functional form
f3 =
pG
C +G
.
The concentration of glucose that where glycogen is produced at half its maximal
rate is C.
Diacylglycerol Production, f4
The myocellular lipid stores are converted to DAG when concentrations are high.
However the conversion rates leading from myocellular lipids to DAG aren’t known,
and the functional form ought to be as simple as possible. We assume that ∂
∂F
(f4) > 0
and likely that ∂
∂D
(f4) ≤ 0. Thus I chose a production rate, d, that is linearly
proportional to the concentration of IMCL, with conversion ratio c:
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f4 = dF.
Diacylglycerol Inhibition of Glucose Transport, f5
The elevated concentration of DAG in the cell leads to activation of protein kinase
C θ (PKCθ) which phosphorylates a particular residue on the insulin receptor sub-
strate. This phosphorylation shuts off the downstream insulin action pathway, which
in turn does not allow intracellular GluT4 to be shuttled to the cell surface. Thus
the membrane bound GluT4 is not replaced when they are inactivated, leading to a
diminished glucose transport into the myocyte. Therefore, we can deduce that f5 is
a monotonically decreasing function of D, but the shape is unknown. For simplicity,
we model this interaction by
f5 =
n
n+D
,
where n is the concentration of DAG that ends up reducing glucose infusion by one
half.
2.1.2 Long-term Model: Function Selection
The key differences between the short-term and long-term model are in the selec-
tion of functional forms for the malonyl-CoA induced reduction of fatty acid transport
across the mitochondrial membranes and the addition of glycogen returning to the
available glucose compartment. Since long term dynamics see intermittent intervals
of feeding and fasting, we must account for the reversion of glycogen into readily
metabolized byproducts.
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Glucose and Fatty Acid Metabolism, (f1 and f2)
For algebraic simplicity and to enable simplified analysis, we exchange the M-CoA
regulating term with an easier form. In this modification, we substitute exp(−qM)
with 1
1+qM
to get
f1(G,F,M) =
mgpgG
k + pgG+
pf
1+qM
F
and
f2(G,F,M) =
mf
pf
1+qM
F
k + pgG+
pf
1+qM
F
.
Glycogen regulation, f3
Glycogen in myocytes supplements the available glucose in times when blood glucose
concentration is low, or in times of exercise. Then it is important that lower con-
centrations of glucose in the cell elicits a glycolysis response to maintain favorable
cellular levels of glucose. Additionally, care is taken to prevent a futile cycle in which
glucose is being converted to glycogen at the same time that glycogen is converted to
glucose. Hence f3 < 0 when glucose is below a threshold gy and f3 > 0 when glucose
is above this threshold. Additionally, glycogen can only be stored and not reverted
when no glycogen is present, f3|Y=0 ≥ 0, and glycogen can only be reverted and not
stored when glucose is depleted, f3|G=0 ≤ 0.
In the cell, glycogen metabolism is regulated by insulin, glucagon, and metabo-
lite concentrations (i.e. AMP and ATP). After a meal, insulin turns off glycogen
phosphorylase, a necessary molecule in the metabolism of glycogen, and during times
of fasting, glucagon turns it on. Additionally, high concentrations of AMP turn on
glycogen phosphorylase in order to produce ATP, and as ATP levels rise, glycogen
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phosphorylase is turned off. Hence we construct a piecewise function using glucose
concentration in the muscle cell as a rough proxy for the presence of insulin, glucagon,
or metabolites.
f3(G, Y ) =

Pf (G−gy)
(
1− Y
my
)
Cu+(G−gy) , G ≥ gy, Y < my
0, G ≥ gy, Y ≥ my
PrY (G−gy)
Cl+gyY
, G < gy
Then f3 is continuous, and bounded above by Pf , the maximal forward rate of
glycogen storage, and below by −Pr, the maximal reversion rate of glycogen to glu-
cose. Both Cu and Cl are shape parameters indicating a half maximal conversion rate.
Finally, we will assume the glycogen compartment has no secondary means of
offloading stored glycogen. In reality, consuming so many excess carbohydrates that
glycogen stores are continually saturated leads to de novo lipid synthesis. Considering
this extreme case in future models may lead to interesting results.
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Chapter 3
EUGLYCEMIC-HYPERINSULINEMIC CLAMP MODEL
The short term model is a functionally simple model designed for parameter esti-
mation against biological data. The full model with function substitutions is displayed
in (3.1).
G˙ = Gin
n
n+D
− mgpgG
k + pgG+ pfe−qMF
− pG
C +G
Y˙ =
pG
C +G
F˙ = Fin − mfpfe
−qMG
k + pgG+ pfe−qMF
− dF (3.1)
D˙ = cdF − µD
M˙ =
amgpgG+ bmfpfe
−qMF
k + pgG+ pfe−qMF
− rM
3.0.1 Analysis
Theorem 1 All solutions of system (3.1) with positive initial conditions remain pos-
itive.
Proof: Consider a trajectory Φ(t,X0) with Φ(0, X0) = X0 ∈ R5+0 , then this tra-
jectory stays positive unless any one of the variables cross to negative. Since the
functions are at least C1(R+), the Picard-Lindelo¨f theorem gives us that solutions ex-
ist for some maximal interval and are unique. Suppose there is a time T > 0 such that
Φ(T,X0) 6∈ R5+0 , then by continuity of the flow and intermediate value theorem, there
is a first time 0 < t∗ < T the trajectory crosses the boundary. Additionally, the vari-
able must cross 0 with negative velocity, and not simply approach 0 asymptotically.
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Then we simply need to show that each of the 5 variables cannot be the first to cross
this boundary with negative velocity. Suppose then that G is the first to go negative,
but G˙|G=0 = Ginf5(D) > 0 which contradicts our assumptions, then G cannot be the
first direction of crossing. Since f3 ≥ 0 always holds, Y cannot be the first variable
to cross. Suppose F as the first variable to become negative, but F˙ |F=0 = Fin > 0
contradicts our assumptions. Then we check D: D˙|D=0 = cf4(F, 0) ≥ 0 also has
non-negative velocity. Finally, we assume that M is the first variable to become neg-
ative, but again M˙ |M=0 = aGf1(F,G, 0)+bFf2(F,G, 0) ≥ 0 gives us our final required
contradiction. Therefore, by contradiction, all positive trajectories remain positive. 
Solutions to the system are not guaranteed to be bounded, but glycogen (Y ) is a
sink. Consider the 4 dimensional system without glycogen,
G˙ = Gin
n
n+D
− mgpgG
k + pgG+ pfe−qMF
− pG
C +G
F˙ = Fin − mfpfe
−qMG
k + pgG+ pfe−qMF
− dF
D˙ = cdF − µD (3.2)
M˙ =
amgpgG+ bmfpfe
−qMF
k + pgG+ pfe−qMF
− rM
Theorem 2 Define
Gˆ =
−B +
√
B2 + 4pgCGin(mg + p−Gin)(k + pfFind )
2pg(mg + p−Gin) ,
B = pgC(mg −Gin) + (k + pfFin
d
)(p−Gin).
Let S be a cube in R4+0 with corners at the origin and (Gˆ, Find ,
cdFin
dµ
,
amg+bmf
r
). The
subsystem (3.2) is invariant in S if mg + p > Gin.
Proof: The system is bounded below by 0, so we need to show it is also bounded
above. Let Φ(t,X0) be the flow of the system with Φ(0, X0) ∈ S. Suppose there is a
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time T > 0 such that Φ(T,X0) 6∈ S, then there must be a first time 0 < t∗ < T the
flow crosses the boundary ∂S. Then we consider each variable as the first direction
in which the boundary is crossed, at which time all other variables are assumed to
be in the interior of S. If the variable crosses, then it must do so with positive time
derivative. Suppose F is the first to cross the upper boundary. Let F ∗ ≥ Fin
d
. Then
F˙ |F ∗ = Fin − pfe
−qMF ∗
k + pgG+ pfe−qMF ∗
− dF ∗ ≤ − pfe
−qMF ∗
k + pgG+ pfe−qMF ∗
< 0.
So F must be bounded above by Fin
d
. Suppose D∗ ≥ cdF ∗
µ
. Then
D˙|D∗ = cdF − µD∗ ≤ cdFin
d
− cdFin
dµ
µ = 0.
So D is bounded above by cdFin
dµ
. Suppose M is the first to cross. Let M∗ ≥ amg+bmf
r
.
Then
M˙ |M∗ = amgpgG+ bmfpfe
−qM∗F
k + pgG+ pfe−qM
∗F
− rM∗ < amg + bmf − ramg + bmf
r
= 0.
So M is bounded above by
amg+bmf
r
. Lastly, suppose G is the first to cross. Let
G∗ ≥ Gˆ. Then
G˙|G=G∗ = Gin n
n+D
− mgpgG
∗
k + pgG∗ + pfe−qMF
− pG
∗
C +G∗
,
and substitute values of other variables, restricted by their upper bound to get
≤ Gin − mgpgG
∗
k + pgG∗ + pf Find
− pG
∗
C +G∗
.
Combine terms,
=
Gin(C +G
∗)(k + pgG∗ + pf Find )−mgpgG∗(C +G∗)− pG∗(k + pgG∗ + pf Find )
(C +G∗)(k + pgG∗ + pf Find )
,
and collect coefficients on powers of G∗,
=
−pg(mg + p−Gin)G∗2 +
(
pgC(mg −Gin) + (k + pfFind )(p−Gin)
)
G∗ + CGin(k +
pfFin
k )
(C +G∗)(k + pgG∗ + pf Find )
.
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Then the numerator is a quadratic with respect to G∗, with a positive constant
term and negative leading coefficient (under the presumption that mg + p > Gin),
hence there is a positive real zero above which the numerator is negative. Let B =
pgC(mg−Gin)+(k+ pfFind )(p−Gin) and call Gˆ the positive solution to the quadratic,
then
Gˆ =
−B +
√
B2 + 4pgCGin(mg + p−Gin)(k + pfFind )
2pg(mg + p−Gin)
hence G∗ ≥ Gˆ gives
=
−pg(mg + p−Gin)G∗2 +
(
pgC(mg −Gin) + (k + pfFind )(p−Gin)
)
G∗ + CGin(k +
pfFin
k )
(C +G∗)(k + pgG∗ + pf Find )
≤ 0
Thus G∗ is bounded above by Gˆ. Therefore, by contradiction, system (3.2) is invari-
ant in S. 
3.0.2 Parameter Estimation
The initial focus of the research is to determine biologically relevant parameters
for the model. Data from previous research (Roden et al., 1996) was extracted using
DataThief and used for estimation (Fig. 3.1). The research employed euglycemic-
hyperinsulinemic clamp methods with fatty acid infusion, and they recorded blood
metrics for 6 hours. The glucose infusion rate is adjusted to keep plasma concentra-
tions constant, and the “stable” infusion rate multiplied by .7 to account for muscle
uptake is used for Gin since about 70% of blood sugar is taken up by muscle. The
fatty acid infusion is constant at 1.5ml/min, however the proportion that is taken
up by muscles is not given, so we have to estimate this under a constraint that the
maximum infusion must be less than 15ml/min. All other parameters are varied and
estimated using 6 datasets.
A total of 4 data sets are used to fit the parameters: glucose oxidation rate for
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Figure 3.1: Glucose Oxidation Rate and ∆ Glycogen for High Fat (Open) and Low
Fat (Closed) Infusion. Data Extracted From (Roden et al., 1996).
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both the high fat and low fat infusion rates and change in glycogen for both high
and low fat infusion. We estimated parameters comparing the model simulation to
all four datasets simultaneously.
Iterative Latin Hypercube Shrinking Method
A hypercube is constructed of feasible parameter values by selecting a maximum
and minimum for each parameter. Thousands of points in the parameter space were
selected from an ordered uniform distribution of parameters using Latin Hypercube
Sampling. Each set of parameters were used to simulate the system for 360 minutes,
and the output was used to calculate the glucose oxidation rate and absolute change
in glycogen to compare with the data. The data was normalized to span a range from
0 to 1 by scaling the data with
vi − vmin
vmax − vmin
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where vmax and vmin are the largest and smallest data values for dataset v, and vi is
the value of point i. This scaling avoids an issue when fitting the model to multiple
datasets with different orders of magnitude. Instead of an absolute squared difference,
it is a relative squared difference. The simulation data was similarly scaled with
xi − vmin
vmax − vmin
where xi is the simulated model at the point corresponding to time vi. The mean
squared error for each dataset is then calculated by∑n
1 (xi − vi)2
n(vmax − vmin)2
and the 4 data sets are summed with weights ωi, i = 1, 2, 3, 4, to control subjective
importance of the fit ,i.e. which data set we want to prioritize fit. This avoids falling
into local minima that strongly fits more simply “shaped” data but does not match
the important dynamics of another dataset.
The point in the parameter space that yielded the lowest mean squared error was
selected as a new center value for the hypercube, the max and min bounds for each
parameter was shrunk around this new center, and LHS was again used to sample
another few thousand points. This continued until the process stabilizes around a
local minima. By this, we mean that either the difference between the best fit of
multiple subsequent fit attempts is within a predetermined tolerance, or the size of
the hypercube is smaller than some tolerance. Since the hypercube is shrunk after
each attempt, this yields a predetermined maximum number of possible runs before
the size of the hypercube is sufficiently small to consider estimation procedure over.
This method allows for exploration over a hypothesized feasible region, and resolu-
tion effectively increases as the same number of points are iteratively selected from
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smaller regions. Hence, this method balances exploration and fine tuning. The major
downfall of this method is the tendency for the system to settle on a local minima
and stop exploring the entire feasible region. If exploration is emphasized, then the
hypercube is shrunk slowly, and convergence may take a very long time. However, if
the hypercube is shrunk too quickly, then the algorithm becomes stuck in an early
region of best fit. For this reason, a more robust system was implemented, where
each iteration acts as feedback for the next.
Particle Swarm Optimization
The iterative LHS shrinking method is designed to shrink toward a local minima.
This unfortunately results in a lack of exploration of the parameter space. For exam-
ple, if the global minimum exists in a small subset of the parameter space, but the
region around the global minimum yields a relatively higher average squared error
then another local minimum in the searching region, then there is a chance that the
search region will shrink and center around the local minimum, excluding the global
minimum from the search region. This scenario is especially prevalent when param-
eter ranges are chosen to include 0, since parameters that should be on the order of,
for example 10−3, could have their global minima excluded from the search region if it
shrinks around a local minima sufficiently far from 0. Therefore, a method of param-
eter estimation that allows for exploration of the parameter space is ideal, especially
when information about the order of magnitude of some parameters is unknown. Par-
ticle swarm optimization (PSO) evolves a set of mobile points in the parameter space
to seek a global minima while still exploring local minima.
The method of PSO defines an initial collection of points in the search region of
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the parameter space,
pi(t) = (ρ1, ρ2, . . . , ρm), i = 1, 2, . . . , n,
where t ∈ N is the iteration step, n is the size of the swarm (number of points),
ρk, k = 1, . . . ,m are values of the parameters being estimated, and m is the number
of estimated parameters. There are various methods of assigning these points, but
we uniformly randomly select points in a designated search region for our algorithm,
i.e.
ρk ∈ ((ρk)min, (ρk)max).
Each point initializes a random velocity in the direction of every parameter being
estimated and it’s starting location is recorded as that point’s best minimizing location
(gi),
vi(t) = (δ1, δ2, . . . , δm), i = 1, . . . , n,
where δk is a real number, bounded in magnitude such that |δk| < ((ρk)max −
(ρk)min)/2, e.g. the particle cannot traverse more than half the initial search region in
one step. The velocities in each direction are randomly determined on initialization.
Additionally, the swarm of points all know the best minimizing location of the whole
swarm,
s = min{gi, i = 1, . . . , n}.
The algorithm then iteratively updates the particles’ locations by
pi(t+ 1) = pi(t) + vi(t),
and then updates the new velocity,
vi(t+ 1) = ω1vi(t) + ω2(gi − pi(t+ 1)) + ω3(s− pi(t+ 1)),
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where ω1 is a weight on inertia, ω2 is a weight on a particles “desire” to move toward
its own recorded local minima, and ω3 is a weight on a particles “desire” to move
toward the globally known minima.
A key decision is how to assign the weights ω1, ω2, ω3 since these drastically af-
fect the system. First, ω1 determines the particles’ exploration of the parameter
space. Values greater than one promote a stubbornness to continue on their current
path and look for new minima, whereas values less than one place more emphasis
on drifting toward known minima and only searching the local area. Hence ω1 has
an effect on precision, where small values give small but thorough search areas. The
weights on moving toward locally known and the globally known minima affect clus-
tering. A strong weight toward the global minima provides a single large cluster
and thoroughly searched area around s. On the other hand, a strong weight toward
individually known minima potentially leads to multiple clusters or pools of parti-
cles searching their own areas. Different landscapes may require different choices of
weights, and debate continues on which to use.
Furthermore, weights need not be static. A common modification is to provide
a decreasing inertial weight, ω1(t), that promotes exploration early in the algorithm,
then tends toward a more thorough local exploration. Then the initial weight, func-
tion choice, and rate of weight reduction become relevant topics of consideration. For
initial results in this project, constant weights are used.
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Parameter Estimation Results
The high versus low fatty acid influx to the muscle cells was estimated to be a ratio of
9.5:1 (i.e. F highin = 9.5F
low
in ) since this was the ratio of high infusion to low infusion in
the study. Thus the model is a fit to both high and low triglyceride infusion scenarios
with all other parameters fixed.
Table 3.1: Variable and Parameter Descriptions
Variable Initial Condition Description Units
G F (0) = 4.9 Intramuscular Glucose mg/kg
Y Y (0) = 24.1 Muscle Glycogen mg/kg
F F (0) = 1.2 10−2 Intramuscular fatty acids mg/kg
D D(0) = 4.7 10−2 Diacylglycerol mg/kg
M M(0) = 1.1 10−1 Intramuscular Malonyl-CoA mg/kg
Parameter Value Description Units
Gin 1.4 Glucose infusion rate (Roden et al., 1996) mg/kg-min
Fin 1.7 10
−3 Fatty acid infusion rate mg/kg-min
a 8.6 10−1 Glucose to M-CoA Conversion unitless
b 1.1 10−3 Fatty acid to M-CoA Conversion unitless
k 50* Metabolism Half-Saturation Constant mg/kg
pg 1.1 10−1 Proportion of G Available For Metabolism unitless
pf 8.3 10
−1 Proportion of F Available For Metabolism unitless
mg 4.6 Maximum Glucose Metabolism Rate mg/kg-min
mf 1.2 10
−1 10−1 Maximum Fatty Acid Metabolism Rate mg/kg-min
q 1 M-CoA Induced Fatty Acid Transfer Reduction kg/mg
r 4.1 10−1 Decay Rate of M-CoA 1/min
p 1.7 Conversion Rate of Glucose to Glycogen 1/min
C 16.4 Half Saturation for G→ Y Conversion mg/kg
d 2.3 10−3 Production Rate of DAG by FFA unitless
µ 1.5 10−2 Decay Rate of DAG 1/min
n 3.2 10−1 Half Max Reduction of Insulin Action by DAG mg/kg
*: k is absorbed into pf and pg during estimation to reduce redundancy
When comparing results from the table to clinical measurements and approxima-
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Figure 3.2: Model Fit to Data
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tions, certain conversions need to be taken into account. For example, the maximal
fat oxidation rate has been measured to be between 0.27-0.52 g/min (Dandanell et al.,
2017) with a resting rate of about 0.15 g/min for patients with a mean fat free mass
was between 62 and 70 kg. The estimated skeletal muscle mass is at least half the
free fat mass (Kimyagarov et al., 2010), or 31-35kg (this ratio is calculated for elderly
individuals). Hence the expected upper limit for mf is 7.714 − 16.774 mg/kg-min,
while the resting rate should be less than 4.286 mg/kg-min. Both the fit for mg and
mf match these requirements.
Furthermore, the model fits the dynamics very well for both the high and low fatty
acid infusion scenarios (Fig. 3.2). The simulation fits the transient dynamics seen in
(Roden et al., 1996), and can be used then to predict the effects of the euglycemic-
hyperinsulinemic clamp on other intracellular behaviors (Fig. 3.3). The percent of
maximal glucose infusion can be calculated by the predicted DAG concentration as
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Figure 3.3: Intracellular Concentrations Predicted for Duration of Clamp Study
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well, which could give insight into how much glucose is being utilized by non-muscle
tissues. Additionally, the simulation in Fig. 3.4 demonstrates that under these par-
ticular parameters, the longer term dynamics reach equilibria for the subsystem (3.2)
while glycogen stores are still submaximal. However, it is likely that once glycogen
stores in muscles reach maximum capacity, the patients will become increasingly ill
under hyperglycemia. Notably, our short term model does not apply in cases when
glycogen is at maximum capacity.
The DAG-induced insulin resistance function, f5(D) =
n
n+D
, is less than one so
long as there is active DAG in the lipid membrane. This condition is biologically
feasible, as there is always some concentration of DAG available to activate PKC.
Hence the parameter choice for Gin is allowed to be greater than our expected glu-
cose infusion rate since the parameter’s function in our model is to act as a maximal
infusion rate under ideal, non-regulated conditions. In this interpretation, it makes
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Figure 3.4: Intracellular Concentrations Predicted Beyond Duration of Clamp Study
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sense that in the low-fat case, Figs. 3.3 and 3.4 show that “insulin resistance” exists
but at a lower level than in the high fat case.
3.0.3 Uncertainty Quantification
The parameter estimation algorithm compares outputs for low and high fatty
acid inflow simultaneously for glucose oxidation and change in glycogen. Not only
is the system highly nonlinear, but it might be unknown what range of values some
parameters might take on. Some parameters have a stronger effect on the quality of fit
than others, so sensitivity analysis is performed on the sum of squared errors (SSE) for
each of the 4 data sets in order to determine how elastic the mean squared error is to
parameter perturbations. The elasticity is calculated numerically for the parameter
set determined by estimation using a difference quotient. For each parameter (or
initial condition), ρ, the elasticity Eρ of SSE(·; ρ) is calculated as
40
Eρ =
∣∣∣∣dSSEdρ
∣∣∣∣ ρSSE = |SSE(·; ρ+ )− SSE(·; ρ)| ρSSE(·; ρ)
for some  > 0.
The parameter that had the highest effect on the fit of all the models is Gin, which
is unsurprising since both glucose oxidation and glycogen storage are directly related
to glucose availability. It is also obvious that glycogen has no effect on glucose oxida-
tion since the concentration of muscle glucose does not directly affect the dynamics
of any other state variable. Besides Gin, Fin comes in as a parameter for which the
fit is rather elastic, which indicates that the concentration of blood fatty acids and
their infusion into the cell is an important factor in the dynamics of the system.
Figure 3.5: Uncertainty Quantification for the Squared Error Glucose Oxidation Fit
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The main difference in elasticity between the fit for the oxidation and ∆ glyco-
gen data sets is that oxidation is more elastic to changes in the glucose metabolism
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parameters (k, pg, pf , and mg) whereas the glycogen storage is more sensitive to pa-
rameters modifying Gin (n, d, and C) as well as the glycogen storage rate (p and
C). Finally, the parameters controlling concentrations of M-CoA seem to be rather
inelastic (a, b, and q), whereas the degradation rate of M-CoA (r) seems to have an
unexpectedly high effect on the fit of both datasets. This elasticity of the system
to M-CoA degradation may be due to the regulatory effects that it has on keeping
the concentration, M , relatively constant. In that way, it’s possible that the fit is
sensitive to r in the same way it is sensitive to pf .
Figure 3.6: Uncertainty Quantification for the Squared Error of ∆ Glycogen Fit
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The lack of elasticity on M suggests that the fatty acid regulation dynamics may
not play an important role in the system at the concentrations that our parameter
estimation results suggest. It is possible that the effect of M on the system would
be more poignant if we found another local minima in the parameter space with a
similar fit. A more global understanding of the system’s feasible parameter regions is
needed to make more specific claims.
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Chapter 4
LONG TERM CHRONIC INSULIN RESISTANCE MODEL
In chapter 3, the model was designed to fit clinical data over a short period of
time during a euglycemic Hyperinsulinemic clamp with fatty acid infusion. As such,
the model only admitted flow of glucose into the glycogen compartment, but no flow
in the reverse direction. In day to day life, however, glycogen is stored or utilized
depending on the cellular environment and energy needs. Hence, it is necessary to
consider the conversion of glycogen back to glucose when necessary – namely when
available glucose concentrations fall below a threshold.
This additional reversion of glycogen back into glucose allows the system to remain
bounded, and long term dynamics to be studied. Additionally, the goal of the long
term model is not for parameter estimation or data fitting, but mathematical analy-
sis. To this end, we simplify the functional form by which mitochondrial metabolites
(namely malonyl-CoA) affect fatty acid transfer into the mitochondria. The system
of equations in (4.1) is the complete long term model with functions as described in
chapter 2.
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G˙ =
nGin
n+D
− mgpgG
k + pgG+
pf
1+qM
F
−

Pf (G−gy)
(
1− Y
my
)
Cu+(G−gy) , G ≥ gy, Y < my
0, G ≥ gy, Y ≥ my
PrY (G−gy)
Cl+gyY
, G < gy
Y˙ =

Pf (G−gy)
(
1− Y
my
)
Cu+(G−gy) , G ≥ gy, Y < my
0, G ≥ gy, Y ≥ my
PrY (G−gy)
Cl+gyY
, G < gy
(4.1)
F˙ = Fin −
mf
pf
1+qM
F
k + pgG+
pf
1+qM
F
− dF
D˙ = cdF − µD
M˙ =
amgpgG+ bmf
pf
1+qM
F
k + pgG+
pf
1+qM
F
− rM
Definition 1 A finite system of ordinary differentiable equations defined on domain
D ∈ Rn with parameter vector ρ
X˙ = Fi(t,X; ρ), X ∈ Ri
is said to be Piecewise Smooth if it is smooth on countably many regions, Ri ∈ Rn,
with nonempty interior and
⋃
Ri = D ∈ Rn. (Bernardo et al., 2008)
Definition 2 Put Σij = Ri ∩Rj, i 6= j, then Σ =
⋃
i 6=j Σij is the switching mani-
fold. (Bernardo et al., 2008)
Since the function, f3 is piecewise continuous, with domains depending on state
variables, this system is a piecewise smooth dynamical system. The system can be
alternatively represented in PWS notation by
X˙ = (G˙, Y˙ , F˙ , D˙, M˙)> = Fi(X, h(X, ρ); ρ), i = 1, 2, 3
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where h(X, ρ) is the switching condition, Fi is determined by which state the switch-
ing condition is in, and ρ is the set of parameters.
We have F1 defined for G > gy, Y < my, F2 for G > gy, Y > my, and F3 for
G < gy. We call the boundary Σ = {G, Y |G > gy and Y = my, or G = gy} the
switching manifold. The switching condition takes the value h(X, ρ) = 0 for X ∈ Σ
and h(X, ρ) 6= 0 for X 6∈ Σ. Then Fi is simply the right hand side of system (4.1) for
each of the relevant domains in the piecewise function. Hence
F1 =

nGin
n+D
− mgpgG
k+pgG+
pf
1+qM
F
− Pf (G−gy)(1−
Y
my
)
Cu+(G−gy)
Pf (G−gy)(1− Ymy )
Cu+(G−gy)
Fin − mf
pf
1+qM
F
k+pgG+
pf
1+qM
F
− dF
cdF − µD
amgpgG+bmf
pf
1+qM
F
k+pgG+
pf
1+qM
F
− rM

,
F2 =

nGin
n+D
− mgpgG
k+pgG+
pf
1+qM
F
0
Fin − mf
pf
1+qM
F
k+pgG+
pf
1+qM
F
− dF
cdF − µD
amgpgG+bmf
pf
1+qM
F
k+pgG+
pf
1+qM
F
− rM

, F3 =

nGin
n+D
− mgpgG
k+pgG+
pf
1+qM
F
− PrY (G−gy)
Cl+gyY
PrY (G−gy)
Cl+gyY
Fin − mf
pf
1+qM
F
k+pgG+
pf
1+qM
F
− dF
cdF − µD
amgpgG+bmf
pf
1+qM
F
k+pgG+
pf
1+qM
F
− rM

.
The dynamics of the PWS system act as if we glued together each of the three
functions. The boundaries along the switching manifold introduce more interesting
dynamics.
4.0.1 Preliminary Analysis
Theorem 3 Solutions to system (4.1) exist and are unique
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Proof : By the Picard-Lindelo¨f theorem, if Fi is continuous and Lipschitz then so-
lutions to system (4.1) exist and are unique. Since continuously differentiable and
bounded implies Lipschitz, We tackle both by showing the system is C1(R,R5) on
the interior of the regions separated by the switching manifold. The Jacobian of the
system is
G ≥ gy, Y < my:

− mgpg(k+
pf
1+qM F )
(k+pgG+
pf
1+qM F )
2
− CuPf (1−
Y
my
)
(Cu+G−gy)2
Pf (G−gy)
my(Cu+G−gy)
mgpg
pf
1+qMG
(k+pgG+
pf
1+qM F )
2
− nGin(n+D)2 −
qmgpg
pf
1+qMGF
(1+qM)(k+pgG+
pf
1+qM F )
2
CuPf (1− Ymy )
(Cu+G−gy)2 −
Pf (G−gy)
my(Cu+G−gy) 0 0 0
pgmf
pf
1+qM F
(k+pgG+
pf
1+qM F )
2
0 − mf
pf
1+qM (k+pgG)
(k+pgG+
pf
1+qM F )
2
− d 0 qmf
pf
1+qM F (k+pgG)
(1+qM)(k+pgG+
pf
1+qM F )
2
0 0 cd −µ 0
pg(akmg+(amg−bmf ) pf1+qM F )
(1+qM)(k+pgG+
pf
1+qM F )
2
0
pf
1+qM (bkmf−pg(amg−bmf )G)
(1+qM)(k+pgG+
pf
1+qM F )
2
0 − q
pf
1+qM F (bmfk−pg(amg−bmf )G)
(1+qM)(k+pgG+
pf
1+qM F )
2

1
G ≥ gy, Y ≥ my:

− mgpg(k+
pf
1+qM F )
(k+pgG+
pf
1+qM F )
2
0
mgpg
pf
1+qMG
(k+pgG+
pf
1+qM F )
2
− nGin(n+D)2 −
qmgpg
pf
1+qMGF
(1+qM)(k+pgG+
pf
1+qM F )
2
0 0 0 0 0
pgmf
pf
1+qM F
(k+pgG+
pf
1+qM F )
2
0 − mf
pf
1+qM (k+pgG)
(k+pgG+
pf
1+qM F )
2
− d 0 qmf
pf
1+qM F (k+pgG)
(1+qM)(k+pgG+
pf
1+qM F )
2
0 0 cd −µ 0
pg(akmg+(amg−bmf ) pf1+qM F )
(1+qM)(k+pgG+
pf
1+qM F )
2
0
pf
1+qM (bkmf−pg(amg−bmf )G)
(1+qM)(k+pgG+
pf
1+qM F )
2
0 − q
pf
1+qM F (bmfk−pg(amg−bmf )G)
(1+qM)(k+pgG+
pf
1+qM F )
2

1
G < gy:

− mgpg(k+
pf
1+qM F )
(k+pgG+
pf
1+qM F )
2
− PrYCl+gyY −
ClPr(G−gy)
(Cl+gyY )2
mgpg
pf
1+qMG
(k+pgG+
pf
1+qM F )
2
− nGin(n+D)2 −
qmgpg
pf
1+qMGF
(1+qM)(k+pgG+
pf
1+qM F )
2
PrY
Cl+gyY
ClPr(G−gy)
(Cl+gyY )2
0 0 0
pgmf
pf
1+qM F
(k+pgG+
pf
1+qM F )
2
0 − mf
pf
1+qM (k+pgG)
(k+pgG+
pf
1+qM F )
2
− d 0 qmf
pf
1+qM F (k+pgG)
(1+qM)(k+pgG+
pf
1+qM F )
2
0 0 cd −µ 0
pg(akmg+(amg−bmf ) pf1+qM F )
(1+qM)(k+pgG+
pf
1+qM F )
2
0
pf
1+qM (bkmf−pg(amg−bmf )G)
(1+qM)(k+pgG+
pf
1+qM F )
2
0 − q
pf
1+qM F (bmfk−pg(amg−bmf )G)
(1+qM)(k+pgG+
pf
1+qM F )
2

1
Each element of the Jacobian matrices is continuous, bounded on their respec-
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tive domain, and defined for all positive G, Y, F,D,M . Hence the RHS of system
(4.1) is Lipschitz on the interior of each region separated by the switching manifold.
Therefore unique solutions to (4.1) are guaranteed to exist for any initial condition
that is an interior point of a region separated by the switching manifold, at least on
some finite time interval. For initial conditions on the switching manifold, we show
that the functions are locally Lipschitz. We test the conditions on the three distinct
sections of the switching manifold: G0 ≥ gy and Y0 = my, G0 = gy and Y0 ≥ my,
and G0 = gy and Y0 < my. Since the equations only differ by the value of f3, we
show that f3 is Lipschitz on the switching manifold, since the sum of finitely many
Lipschitz functions is Lipschitz. Put K = max
{
Pf
my
, Pr
gy
,
Pf
Cu
}
.
Case 1: G0 ≥ gy and Y0 = my.
Pick G0 ≥ gy and set Y0 = my. Then let α, β > 0 and consider
|f3(G0, Y0 − α)− f3(G0, Y0 + β)|.
Since Y0 − α < my and Y0 + β > my, we have
f3(G0, Y0 − α) =
Pf (G− gy)
(
1− my−α
my
)
Cu +G− gy
and f3(G0, Y0 + β) = 0 Hence
|f3(G0, Y0 − α)− f3(G0, Y0 + β)| =
∣∣∣∣∣∣
Pf (G0 − gy)
(
1− my−α
my
)
Cu +G0 − gy
∣∣∣∣∣∣
≤ Pf
(
1− my − α
my
)
=
Pf
my
α <
Pf
my
|α + β|
=
Pf
my
|(Y0 − α)− (Y0 + β)| ≤ K|(Y0 − α)− (Y0 + β)|
Since G0 ≥ gy, α, β were chosen arbitrarily, f3 is Lipschitz on this section of the
switching manifold.
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Case 2: G0 = gy and Y0 ≥ my.
Pick Y0 ≥ my and set G0 = gy. Then let α, β > 0 and consider
|f3(G0 − α, Y0)− f3(G0 + β, Y0)|.
Since G0 − α < gy and G0 + β > gy, we have
f3(G0 − α, Y0) = − PrY0α
Cl + gyY0
and f3(G0 + β, Y0) = 0. Hence
|f3(G0 − α, Y0)− f3(G0 + β, Y0)| =
∣∣∣∣ PrY0αCl + gyY0
∣∣∣∣ ≤ Prgy |α + β|
≤ Pr
gy
|(G0 − α)− (G0 + β)| ≤ K|(G0 − α)− (G0 + β)|..
Therefore f3 is Lipschitz on this section of the switching manifold.
Case 3: G0 = gy and Y0 < my.
Pick Y0 < my and set G0 = gy. Then let α, β > 0 and consider
|f3(G0 − α, Y0)− f3(G0 + β, Y0)|.
Since G0 − α < gy and G0 + β > gy, we have
f3(G0 − α, Y0) = − PrY0α
Cl + gyY0
and
f3(G0 + β, Y0) =
βPf (1− Y0my )
Cu + β
.
Hence
|f3(G0 − α, Y0)− f3(G0 + β, Y0)| =
∣∣∣∣∣ PrY0αCl + gyY0 + βPf (1−
Y0
my
)
Cu + β
∣∣∣∣∣
≤ Pr
gy
α +
Pf
Cu
β ≤ max
{
Pr
gy
,
Pf
Cu
}
|α + β|
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≤ K|(G0 − α)− (G0 + β)|
Then f3 is Lipschitz on this last section of the switching manifold. Therefore, for any
X0 ∈ R5+0 , solutions to (4.1) exist and are unique. 
Theorem 4 Let ΦX0 ≡ Φ(t,X0), t ≥ 0 be a forward flow of system (4.1) with initial
conditions
Φ(0, X0) = X0 = (G(0), Y (0), F (0), D(0),M(0)) = (G0, Y0, F0, D0,M0) ∈ R5+0
Then Φ(t,X0) ∈ R5+0 for all t > 0 on which ΦX0 is defined. Additionally, ΦX0 is
bounded above.
Proof: Let X0 = (G0, Y0, F0, D0,M0) ∈ R5+0 , and let Φ(t,X0) be the flow of system
(4.1).
Claim 1 (positivity): Φ(t,X0) ∈ R5+0 ∪ {∞} for all t > 0 on which ΦX0 is defined.
Since the RHS of (4.1) is continuous, the integral solutions are continuous in
time. Then by the intermediate value theorem, if there exists T > 0 such that
Φ(T,X0) 6∈ R5+0 , then there is a first time 0 < t∗ < T such that Φ(t∗, X + 0)ei = 0,
where ei = (0, 0, . . . , 1, . . . , 0, 0) with 1 in the i
th position, i = 1, . . . , 5. Furthermore,
in order for the flow to escape R5+0 , we need
d
dt
Φ(t,X0)ei|t=t∗ < 0,
i.e. it must cross that boundary with nonzero velocity. Then we simply check each
time derivative evaluated on the boundary. Suppose for the sake of contradiction that
there exists T > 0 such that Φ(T,X0) 6∈ R5+0 ∪ {∞}, then there is a first crossing
time t∗ > 0. Moreover, suppose that for t = t∗ we have G(t∗) = 0. Then the time
derivative on the boundary is
G˙|G=0 = nGin
n+D
+
PrY gy
Cl + gyY
> 0
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assuming Y,D ≥ 0, which must be true since t∗ is the first time Φ(t,X0) leaves the
positive sector. Continue this for each of the other state variables
Y˙ |Y=0 =

Pf (G−gy)
Cu+(G−gy) , G ≥ gy
0, G < gy
≥ 0,
F˙ |F=0 = Fin > 0,
D˙|D=0 = cdF ≥ 0,
M˙ |M=0 = amgpgG+ bmfpfF
k + pgG+ pfF
> 0.
But none of the time derivatives have negative velocity on the boundary, this con-
tradicts the assertion that there is some time T > 0 where Φ(T,X0) 6∈ R5+0 . Therefore,
Φ(t,X0) ∈ R5+0 for all t > 0 for which ΦX0 is defined.
Claim 2 (boundedness from above):
Let the origin and
(
Gin(k+
pfFin
d
)
pg(mg−Gin) ,max{my, Y0}, Find , cFinµ ,
amg+bmf
r
)
define a hyper-
cube C ∈ R5. We will show that if X0 ∈ C then Φ(t,X0) ∈ C for all t ≥ 0 for which
ΦX0 is defined. Let X0 ∈ C. To show this, it is sufficient to demonstrate that the
time derivative is negative for any state variable outside of C. As with positivity,
assume there is a first time t∗ and first variable to exit C. Hence, we assume that all
other variables not being inspected on the boundary ∂C are on the interior of C.
If F ≥ Fin
d
, then
F˙ = Fin −
mf
pf
1+qM
F
k + pgG+
pf
1+qM
F
− dF ≤ − mf
pf
1+qM
F
k + pgG+
pf
1+qM
F
< 0,
hence F is bounded above.
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If D ≥ cFin
µ
, then
D˙ = cdF − µD < cFin − µD ≤ 0,
hence D is bounded above.
If M ≥ amg+bmf
r
, then
M˙ =
amgpgG+ bmf
pf
1+qM
F
k + pgG+
pf
1+qM
F
− rM < amg + bmf − rM ≤ 0,
hence M is bounded above.
If Y > my, then
Y˙ =
 0, G ≥ gyPrY (G−gy)
Cl+gyY
, G < gy
≤ 0,
hence Y is bounded above by my if Y0 < my or by Y0 if Y0 ≥ my.
Finally, the nature of Y ’s boundedness requires us to consider 2 cases for G:
G ≥ gy, Y ≥ my, and G ≥ gy, Y < my. Note that if G is bounded in both of these
cases, then G is bounded.
Case 1: Begin with
G˙|G≥gy ,Y≥my =
nGin
n+D
− mgpgG
k + pgG+
pf
1+qM
F
≤ Gin − mgpgG
k + pgG+
pf
1+qM
F
replacing M with 0 and F with its upper bound
≤ Gin − mgpgG
k + pgG+
pfFin
d
=
Gin(k + pgG+
pfFin
d
)−mgpgG
k + pgG+
pfFin
d
and rearrange
Gin(k +
pfFin
d
)− pg(mg −Gin)G
k + pgG+
pfFin
d
≤ Gin(k +
pfFin
d
)−Gin(k + pfFind )
k + pgG+
pfFin
d
= 0
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Hence G˙|G≥gy ,Y≥my ≤ 0.
Case 2:
G˙|G≥gy ,Y <my =
nGin
n+D
− mgpgG
k + pgG+
pf
1+qM
F
−
Pf (G− gy)(1− Ymy )
Cu + (G− gy)
But it’s clear by the additional negative term that
G˙|G≥gy ,Y <my ≤ G˙|G≥gy ,Y≥my ≤ 0,
so boundedness is automatic. Thence G is bounded.
Therefore, by contradiction, if X0 ∈ C then Φ(t,X0) ∈ C for all t > 0 for which
ΦX0 is defined. 
Beyond the uniqueness, existence, and invariance of solutions of (4.1), we explore
how the dynamics of the system changes as we progress from a model of a healthy
person, to one with insulin resistance without fatty acid metabolism regulation, and
finally to the full model with insulin resistance and fatty acid metabolism regulation.
4.0.2 Sub-models: Ignoring Mitochondrial Metabolites
We analyze sub-models of (4.1) in order to understand how the dynamics evolve
from a healthy case without DAG, and with DAG. For these cases, the effect of
Malonyl-CoA (M) is ignored due to the highly nonlinear terms that the interaction
introduces. Additionally, sensitivity analysis of the parameters involved in the pro-
duction and function of M-CoA demonstrated that the system is inelastic to their
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perturbations. For these reasons, the M compartment is ignored for further study.
Hence, we seek mathematically tractable equations to clearly understand the system
behavior from the ground up before getting lost in the details analyzing (4.1).
4.0.3 Sub-model: Healthy Individual - No effect of DAG
Suppose that in a healthy individual, the levels of DAG present are too insignif-
icant to influence insulin resistance, then we ignore the compartment and get the
system
G˙ = Gin − mgpgG
k + pgG+ pfF
−

Pf (G−gy)
(
1− Y
my
)
Cu+(G−gy) , G ≥ gy, Y < my
0, G ≥ gy, Y ≥ my
PrY (G−gy)
Cl+gyY
, G < gy
Y˙ =

Pf (G−gy)
(
1− Y
my
)
Cu+(G−gy) , G ≥ gy, Y < my
0, G ≥ gy, Y ≥ my
PrY (G−gy)
Cl+gyY
, G < gy
(4.2)
F˙ = Fin − mfpfF
k + pgG+ pfF
− dF
Then we have fatty acids still converted to other byproducts, but we don’t keep
track of DAG if we assume that its concentration is low enough to cause no effect.
Definition 3 A discontinuous bifurcation (or dicontinuity induced bifurcation)
occurs when a fixed point of a system passes through the switching manifold. (Bernardo
et al., 2008; Simpson et al., 2009)
Note that stability of an equilibrium lying on a swithcing manifold is an open
problem (Bernardo et al., 2008).
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Theorem 5 System (4.2) has a unique equilibrium, (G∗, Y ∗, F ∗), if mg > Gin for
each region. The equilibrium is stable where it exists. The equilibrium is given by
G∗ =
A
pg
(k + pfF
∗),
F ∗ =
(1 +A)(pfFin − dk)−mfpf +
√
((1 +A)(pfFin − dk)−mfpf )2 + 4dkpfFin(1 +A)2
2dpf (1 +A)
,
A =
Gin
mg −Gin .
Furthermore, the system presents a discontinuous bifurcation, that is for
G∗ < gy, Y ∗ = 0,
G∗ > gy, Y ∗ = my,
G∗ = gy, Y ∗ ∈ [0,∞)
The case where G∗ = gy is degenerate and creates a critical line of equilibria.
Proof:
We start by requiring f3(G, Y ) = 0, hence we consider 3 cases:
Case 1: G∗ < gy, Y ∗ = 0
Case 2: G∗ > gy, Y ∗ = my
Case 3: G∗ = gy, Y ∗ = Y ∗ ≥ 0
The dynamics of the full piecewise-continuous system can be understood by “gluing
together” the results of these three cases.
Case 1: G∗ < gy
Substituting Y ∗ = 0 and solving G˙ = 0 for G∗ we get
0 = Gin − mgpgG
∗
k + pgG∗ + pfF ∗
,
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mgpgG
∗ = Gin(k + pgG∗ + pfF ∗),
mgpgG
∗ − pgGinG∗ = Gin(k + pfF ∗),
G∗ =
Gin(k + pfF
∗)
pg(mg −Gin) .
Then we simplify by substituting
A =
Gin
mg −Gin
to get
G∗ =
A
pg
(k + pfF
∗).
necessitating mg > Gin for biologically feasible values of G
∗.
Similarly, we solve for F ∗ by setting F˙ = 0 to get
0 = Fin − mfpfF
∗
k + pgG∗ + pfF ∗
− dF ∗,
into which we substitute G∗
0 = Fin − mfpfF
∗
k + A(k + pfF ∗) + pfF ∗
− dF ∗,
rearrange
mfpfF
∗ + d(k + A(k + pfF ∗) + pfF ∗)F ∗ = Fin(k + A(k + pfF ∗) + pfF ∗),
and collect terms on each power of F ∗, moving everything to the LHS
dpf (1 + A)F
∗2 + [mfpf + (dk − pfFin)(1 + A)]F ∗ − kFin(1 + A) = 0.
Then we find F ∗ as a solution to αF ∗2 + βF ∗ + γ with
α = dpf (1 + A)
β = mfpf + (dk − pfFin)(1 + A)
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γ = −kFin(1 + A)
and since A > 0 we know there is always exactly one positive real root for F ∗ by
Descartes’ rule of signs, since either α, β > 0, γ < 0 or α > 0,β, γ < 0 yields only one
sign change. Solving for F ∗ we get
F ∗ =
−β ±√β2 − 4αγ
2α
which we can ignore the negative, non-biological equilibrium to get
F ∗ =
(1 +A)(pfFin − dk)−mfpf +
√
((1 +A)(pfFin − dk)−mfpf )2 + 4dkpfFin(1 +A)2
2dpf (1 +A)
where the radicand is clearly always positive when A > 0.
The Jacobian of the system evaluated at the equilibria takes the form
J1|G=G∗,Y=0,F=F ∗ =

− mg(k+F ∗pf )pg
(k+F ∗pf+G∗pg)2
Pr
Cl
(gy −G∗) G
∗mgpfpg
(k+F ∗pf+G∗pg)2
0 −PrCl (gy −G∗) 0
F ∗mfpfpg
(k+F ∗pf+G∗pg)2
0 −mfpf (k+G∗pg)+d(k+F ∗pf+G∗pg)2
(k+F ∗pf+G∗pg)2
 .
The full expressions for G∗ and F ∗ are not substituted so as to ease the digestibility
of the analysis. We use the Routh-Hurwitz Criterion to determine stability (Brauer
et al., 2001). The Jacobian has a characteristic polynomial determined by setting
det[λI− J1] = 0 described by λ3 + a1,1λ2 + a1,2λ+ a1,3 = 0 with coefficients
a1,1 =
Pr
Cl
(gy −G∗) + mg(k + F
∗pf )pg
(k + F ∗pf +G∗pg)2
+
mfpf (k +G
∗pg) + d(k + F ∗pf +G∗pg)2
(k + F ∗pf +G∗pg)2
a1,2 =
(
mg(k + F
∗pf )pg
(k + F ∗pf +G∗pg)2
)(
mfpf (k +G
∗pg) + d(k + F ∗pf +G∗pg)2
(k + F ∗pf +G∗pg)2
)
+
(
G∗mgpfpg
(k + F ∗pf +G∗pg)2
)(
F ∗mfpfpg
(k + F ∗pf +G∗pg)2
)
+
(
Pr
Cl
(gy −G∗)
)(
mg(k + F
∗pf )pg
(k + F ∗pf +G∗pg)2
+
mfpf (k +G
∗pg) + d(k + F ∗pf +G∗pg)2
(k + F ∗pf +G∗pg)2
)
(4.3)
a1,3 =
(
Pr
Cl
(gy −G∗)
)[(
mg(k + F
∗pf )pg
(k + F ∗pf +G∗pg)2
)(
mfpf (k +G
∗pg) + d(k + F ∗pf +G∗pg)2
(k + F ∗pf +G∗pg)2
)
+
(
Pr
Cl
(gy −G∗)
)(
F ∗mfpfpg
(k + F ∗pf +G∗pg)2
)]
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The constants, a1,1 and a1,3 are clearly both positive when G
∗ < gy since each term
is independently positive. Then we only need to check
a1,1a1,2−a1,3 =(
mg(k + F
∗pf )pg
(k + F ∗pf +G∗pg)2
+
mfpf (k +G
∗pg) + d(k + F ∗pf +G∗pg)2
(k + F ∗pf +G∗pg)2
)
×
[(
mg(k + F
∗pf )pg
(k + F ∗pf +G∗pg)2
)(
mfpf (k +G
∗pg) + d(k + F ∗pf +G∗pg)2
(k + F ∗pf +G∗pg)2
)
+
(
G∗mgpfpg
(k + F ∗pf +G∗pg)2
)(
F ∗mfpfpg
(k + F ∗pf +G∗pg)2
)
+
(
Pr
Cl
(gy −G∗)
)2(
mg(k + F
∗pf )pg
(k + F ∗pf +G∗pg)2
+
mfpf (k +G
∗pg) + d(k + F ∗pf +G∗pg)2
(k + F ∗pf +G∗pg)2
)]
Hence a1a2 − a3 > 0. Therefore by the Routh-Hurwitz Criterion, this equilibria is
stable when mg > Gin and G
∗ < gy.
Case 2: G∗ > gy
Setting Y ∗ = my and solving for G∗ and F ∗ returns exactly the same results as in
case 1,
G∗ =
A
pg
(k + pfF
∗),
F ∗ =
(1 +A)(pfFin − dk)−mfpf +
√
((1 +A)(pfFin − dk)−mfpf )2 + 4dkpfFin(1 +A)2
2dpf (1 +A)
A =
Gin
mg −Gin .
and the Jacobian of the system is
J2|G=G∗,Y=my,F=F∗ =

− mg(k+F∗pf )pg(k+F∗pf+G∗pg)2
(G∗−gy)Pf
(Cu+G∗−gy)my
G∗mgpfpg
(k+F∗pf+G∗pg)2
0 − (G∗−gy)Pf(Cu+G∗−gy)my 0
F∗mfpfpg
(k+F∗pf+G∗pg)2
0 −mfpf (k+G∗pg)+d(k+F∗pf+G∗pg)2(k+F∗pf+G∗pg)2
 .
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The characteristic polynomial of J2 takes the form λ
3 + a2,1λ
2 + a2,2λ + a2,3 = 0
with coefficients
a2,1 =
(G∗ − gy)Pf
(Cu +G∗ − gy)my +
mg(k + F
∗pf )pg
(k + F ∗pf +G∗pg)2
+
mfpf (k +G
∗pg) + d(k + F ∗pf +G∗pg)2
(k + F ∗pf +G∗pg)2
a2,2 =
(
mg(k + F
∗pf )pg
(k + F ∗pf +G∗pg)2
)(
mfpf (k +G
∗pg) + d(k + F ∗pf +G∗pg)2
(k + F ∗pf +G∗pg)2
)
+
(
G∗mgpfpg
(k + F ∗pf +G∗pg)2
)(
F ∗mfpfpg
(k + F ∗pf +G∗pg)2
)
+
(
(G∗ − gy)Pf
(Cu +G∗ − gy)my
)(
mg(k + F
∗pf )pg
(k + F ∗pf +G∗pg)2
+
mfpf (k +G
∗pg) + d(k + F ∗pf +G∗pg)2
(k + F ∗pf +G∗pg)2
)
(4.4)
a2,3 =
(
(G∗ − gy)Pf
(Cu +G∗ − gy)my
)[(
mg(k + F
∗pf )pg
(k + F ∗pf +G∗pg)2
)(
mfpf (k +G
∗pg) + d(k + F ∗pf +G∗pg)2
(k + F ∗pf +G∗pg)2
)
+
(
(G∗ − gy)Pf
(Cu +G∗ − gy)my
)(
F ∗mfpfpg
(k + F ∗pf +G∗pg)2
)]
Since G∗ > gy, it’s clear that a2,1 > 0 and a2,3 > 0. Then the final condition
a2,1a2,2 − a2,3 =(
mg(k + F
∗pf )pg
(k + F ∗pf +G∗pg)2
+
mfpf (k +G
∗pg) + d(k + F ∗pf +G∗pg)2
(k + F ∗pf +G∗pg)2
)
×
[(
mg(k + F
∗pf )pg
(k + F ∗pf +G∗pg)2
)(
mfpf (k +G
∗pg) + d(k + F ∗pf +G∗pg)2
(k + F ∗pf +G∗pg)2
)
+
(
G∗mgpfpg
(k + F ∗pf +G∗pg)2
)(
F ∗mfpfpg
(k + F ∗pf +G∗pg)2
)
+
(
(G∗ − gy)Pf
(Cu +G∗ − gy)my
)2(
mg(k + F
∗pf )pg
(k + F ∗pf +G∗pg)2
+
mfpf (k +G
∗pg) + d(k + F ∗pf +G∗pg)2
(k + F ∗pf +G∗pg)2
)]
is also positive. Hence, by the Routh-Hurwitz criterion, the equilibrium is stable.
Case 3: G∗ = gy
When G∗ = gy, the implication is that sugar is passing into the muscles at exactly
the rate required for the muscles glucose concentration to be exactly ideal. Hence,
this equilibrium only exists for a specific subset of parameters. Notice above in both
of the two cases that G∗ = A(k + pfF ∗)/pg. Then, by solving G∗ = gy for F ∗, we see
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that
A(k + pfF
∗)/pg = gy
gives us
F ∗ =
pggy − Ak
pfA
.
If we have pggy − Ak > 0 then it is possible for the conditions to exist such that
G∗ = gy. Assume pggy −Ak > 0 holds. Then, we can substitute G∗ = gy and pggy−AkpfA
into F˙ = 0
F˙ ∗ = Fin −
mf
pggy−Ak
A
k + pggy +
pggy−Ak
A
− dpggy − Ak
pfA
= 0
rearrange to isolate Fin, which we rename to Fˆin to denote a special case
Fˆin =
mf (pggy − Ak)
pggyA+ pggy
+
d(pggy − Ak)
pfA
and substitute A = Gin
mg−Gin and simplify the compound fractions
Fˆin =
mf (pggy(mg −Gin)−Gink)
pggyGin + (mg −Gin)pggy +
d(pggy(mg −Gin)− kGin)
pfGin
,
=
mfpfGin(pggy(mg −Gin)−Gink) + dmgpggy(pggy(mg −Gin)− kGin)
mgpggypfGin
,
=
(pggy(mg −Gin)−Gink)(mfpfGin + dmgpggy)
mgpggypfGin
,
=
(mg −Gin)(pggy − Ak)(mfpfA+ dmgpggymg−Gin )
mgpggypfA
.
This clearly requires the two previous conditions mg > Gin and pggy > Ak in order
for a biologically relevant value of Fˆin.
Moreover, we wish to determine a relationship between Fin and Gin, so we can
expand and combine terms to find
Fˆin(Gin) = −
(
mf
mg
+
kmf
gymgpg
)
Gin +
dgymgpg
pfGin
+
(
mf − d
pf
(gypg + k)
)
,
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which is continuous for all Gin > 0,
dFˆin
dGin
(Gin) = −
(
mf
mg
+
kmf
gymgpg
)
− dgymgpg
pfG2in
< 0,
and
lim
Gin→0
=∞, lim
Gin→∞
= −∞.
Thus there can only be a single possible value Fˆin for any Gin. Then this unique value
of Fˆin(Gin) is positive when
pggy − Ak > 0
pggy(mg −Gin)− kGin > 0
Gin <
pggy
pggy + k
mg < mg.
Hence the conditions for G∗ = gy depend on the parameters, and are not always
present.
The expression gives us a single parameter on which we define our bifurcation. In
other words, if Fin < Fˆin then we are in case 1, if Fin > Fˆin then we are in case 2. The
result then when Fin = Fˆin, is that G
∗ = gy and f3(gy, Y ∗) = 0 for all values of Y ∗,
hence Y˙ |G∗=gy = 0 implies the equilibrium can exist for any Y ∗ ≥ 0. The Jacobian
matrix for this set of equilibrium is
J3,1 =

− mg(k+F ∗pf )pg
(k+F ∗pf+gypg)2
− Pf
Cu
(
1− Y ∗
my
)
0
gymgpfpg
(k+F ∗pf+gypg)2
Pf
Cu
(
1− Y ∗
my
)
0 0
F ∗mfpfpg
(k+F ∗pf+gypg)2
0 −mfpf (k+gypg)+d(k+F ∗pf+gypg)2
(k+F ∗pf+gypg)2
 ,
J3,2 =

− mg(k+F ∗pf )pg
(k+F ∗pf+gypg)2
0
gymgpfpg
(k+F ∗pf+gypg)2
0 0 0
F ∗mfpfpg
(k+F ∗pf+gypg)2
0 −mfpf (k+gypg)+d(k+F ∗pf+gypg)2
(k+F ∗pf+gypg)2
 ,
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or
J3,3 =

− mg(k+F ∗pf )pg
(k+F ∗pf+gypg)2
− PrY ∗
Cl+gyY ∗
0
gymgpfpg
(k+F ∗pf+gypg)2
PrY ∗
Cl+gyY ∗
0 0
F ∗mfpfpg
(k+F ∗pf+gypg)2
0 −mfpf (k+gypg)+d(k+F ∗pf+gypg)2
(k+F ∗pf+gypg)2
 ,
depending on if we consider the linearization of the system above G∗ = gy when
Y ∗ < my (3,1), when Y ∗ ≥ my (3,2), or the linearization of the system below G∗ = gy
(3,3). For simplicity of notation, we will replace the elements in the Jacobian matrices
with ji, i = 1, 2, . . . , 9 where the i
th element is counted across from left to right, top
to bottom. Specifically we will use
J3,{1,2} =

j1 0 j3
j4 0 0
j7 0 j9
 .
Then the characteristic equation is λ(λ2 − (j1 + j9)λ + j1j9 − j3j7) = 0. So we
have a trivial eigenvalue λ2 = 0, and the other two eigenvalues (λ1, λ3) are solu-
tions to a quadratic expression. Hence, we can expect λ1, λ3 < 0 if j1 + j9 < 0 and
j1j9 − j3j7 > 0. Note that the biologically feasible solution space limits Y ∈ [0,my],
where my is the maximum glycogen storage concentration. Additionally, the forward
semi-flow for Y is bounded above by my for any 0 ≤ Y (t0) ≤ my, so any scenario in
which Y ∗ > my will be henceforth neglected.
Immediately, we see j1+j9 < 0 when Y
∗ < my for Jacobian (3,1), and it is trivially
negative for (3,2) and (3,3). The second necessary condition after some simplification
is
(J3,1) : j1j9 − j3j7 =
(
mg(k + F ∗pf )pg +mfpfgypg
Pf
Cu
(
1− Y ∗
my
))
(mfpfk + d(k + F
∗pf + gypg)2)
(k + F ∗pf + gypg)4
> 0,
(J3,2) : j1j9 − j3j7 = mgpg(k + F
∗pf )(mfpfk + d(k + F ∗pf + gypg)2)
(k + F ∗pf + gypg)4
> 0,
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or
(J3,3) : j1j9 − j3j7 =
(
mg(k + F ∗pf )pg +mfpfgypg PrY
∗
Cl+gyY
∗
)
(mfpfk + d(k + F
∗pf + gypg)2)
(k + F ∗pf + gypg)4
> 0,
which holds in all three cases.
Hence, we have λ1 < 0, λ2 = 0, and λ3 < 0. The following analysis is conducted
to determine what happens near the critical line (gy, Y,
pggy−Ak
pfA
)
For ease of handling, the system is non-dimensionalized so we can reduce the
number of parameters from 14 to 10. Additionally, we will redefine the system as
X˙ = Fi(X;P ;h(X)) where X = (g, y, f)
>, i = 1 when h(X) ≥ 0, i = 2 when
h(X) < 0, and P is our set of parameters as defined in table (4.1).
Table 4.1: Non-dimensionalized Variable and Parameter Substitutions
Parameter a b ρ m δ γ ξ1 ξ2 ζ1 ζ2
Substitution Ginkmgpggy
Finpf
mgpg
pggy
k
mfpf
mgpg
kd
mgpg
gy
my
Pfk
mgpggy
Prk
mgpggy
Cu
gy
Cl
gymy
g = Ggy y =
Y
my
f =
Fpf
k τ =
tmgpg
k
Define
h(X) = g − 1
Then we have the system
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
g˙
y˙
f˙
 =

F1 =

a− g
1+ρg+f
− ξ1 (g−1)(1−y)ζ1+g−1
γξ1
(g−1)(1−y)
ζ1+g−1
b− mf
1+ρg+f
− δf
 , g ≥ 1
F2 =

a− g
1+ρg+f
− ξ2 y(g−1)ζ2+y
γξ2
y(g−1)
ζ2+y
b− mf
1+ρg+f
− δf
 , g < 1
Hence, the switching manifold is the plane on which g = 1.
Notice that y˙ = γf3, where γ = gy/mg. This indicates biologically that γ << 1
since the maximum storage capacity of glycogen in a cell is of much higher magnitude
compared to the ideal concentration of active glucose. Hence y changes at a slower
pace than g or f . Let the subsystem (g, f)> be the fast dynamics, and y the slow
dynamics. Then we consider the dynamics of the fast system and slow system sepa-
rately. Then the linearization for (g, f)> gives two negative eigenvalues when g∗ = 1.
Hence the fast system has an asymptotically stable equilibrium. Let X∗ = (g∗, f ∗)>
be the equilibrium for the fast system. By the stable manifold theorem (theorem
9.4 in (Teschl, 2012)) there is a neighborhood of X∗ such that the flow described by
g(t) can be described with |g(t) − 1| ≤ Ce−αt, where α < min{|<(λ)||λ is an eigen-
value of J,<(λ) 6= 0}, where J is the Jacobian, and C > 0 depends on the choice of α.
Suppose g0 > 1. Then we can approximate the flow g(t) = 1 + (g0 − 1)e−αt,
where α is chosen as above, and assume that this approximation chooses α such that
C > g0 − 1 > 0. Let y(0) = y0 ∈ (0, 1). Then we substitute
y˙ = γξ1
(g0 − 1)e−αt(1− y)
ζ1 + (g0 − 1)e−αt
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and integrate, ∫
dy
1− y = −γξ1
∫
(g0 − 1)e−αtdt
ζ1 + (g0 − 1)e−αt
letting q = γξ1
α
, we get
− ln |1− y| = −q ln ∣∣ζ1 + (g0 − 1)e−αt∣∣− C1
rearrange to find
C1 = ln
∣∣∣∣ 1− y(ζ1 + (g0 − 1)e−αt)q
∣∣∣∣
and letting C = eC1 , we find by setting y(0) = y0
C =
1− y0
(ζ1 + g0 − 1)q .
Hence we have
y(t) = 1− (1− y0)
(
ζ1 + (g0 − 1)e−αt
ζ1 + g0 − 1
)q
. (4.5)
Then the final long term behavior of y(t) as t→∞ indicates that
y∗ = lim
t→∞
y(t) = 1− (1− y0)
(
ζ1
ζ1 + g0 − 1
)q
.
Hence y increases monotonically near the critical line, and the equilibrium value gets
closer to 1 the closer y0 is to 1 or the farther g0 is from 1. If y0 = 1 then y(t) = 1 and
y∗ = 1. If g0 = 1, then y(t) = y0 and y∗ = y0, hence if y0 = 0, then we have y∗ = 0.
Choose y∗ ∈ (0, 1) and y0 ∈ (0, 1) Then we can choose g0 such that
g0 = ζ1
[(
1− y0
1− y∗
)1/q
− 1
]
+ 1 ≥ 1.
Since y∗ was chosen arbitrarily, any point on the critical line is a potential equilibrium
for y when g0 ≥ 1.
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Similarly, suppose that g0 < 1, then we have the approximation g(t) = 1 − (1 −
g0)e
−αt. Substituting gives us
y˙ = −γξ2y(1− go)e
−αt
ζ2 + y
and dividing both sides by the terms with y separates the equation to become
y˙
ζ2 + y
y
= −γξ2(1− g0)e−αt
which we can integrate with respect to time to give
ζ2 ln |y|+ y = γξ2
α
(1− g0)e−αt + C1.
Combine and exponentiate each side letting C2 = e
C1
yζ2ey = C2e
γξ2(1−g0)
α
e−αt .
Then, we can take the ζ2 root of both sides and divide both sides by the same to
obtain
y
ζ2
ey/ζ2 = Ce
γξ2(1−g0)
ζ2α
e−αt
where C = C
1/ζ2
2 /ζ2. Here we set t = 0 to find
C =
y0
ζ2
e
y0/ζ2− γξ2(1−g0)ζ2α
Finally, we can invoke the Lambert-W function to simplify this to
y(t) = ζ2W
(
y0
ζ2
exp
[
y0
ζ2
+
γξ2(1− g0)
ζ2α
(e−αt − 1)
])
. (4.6)
This approximation has time derivative
y′(t) = −γξ2(1− g0)e
−αtW (·)
1 +W (·) < 0
Hence y(t) is decreasing monotonically. Taking t→∞ we find
y∗ = lim
t→∞
y(t) = ζ2W
(
y0
ζ2
exp
[
y0
ζ2
− γξ2(1− g0)
ζ2α
])
= ζ2W (C).
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Since C ≥ 0 for all y0 ∈ [0, 1], g0 ∈ [0, 1) and W (C) is monotone increasing with
C ≥ 0, the dynamics of y∗ can be determined by the dynamics of C. Then we need
to know how C varies for different values of y0 and g0.
∂C
∂y0
=
e
y0/ζ2− γξ2(1−g0)ζ2α
ζ2
+
y0
ζ22
e
y0/ζ2− γξ2(1−g0)ζ2α > 0
∂C
∂g0
=
y0γξ2
αζ22
e
y0/ζ2− γξ2(1−g0)ζ2α > 0
Hence larger values of y0 give larger values of y
∗ and the further g0 is to the equilibrium
g∗ = 1, the smaller y∗ is. Additionally, W (0) = 0, so y∗ = 0 if C = 0, which happens
precisely when y0 = 0 To check consistency, we determine when y
∗ = 1, or more
concisely when
W (C) =
1
ζ2
.
This, of course, occurs when
1
ζ2
e1/ζ2 = C =
y0
ζ2
e
y0/ζ2− γξ2(1−g0)ζ2α
hence when y0 = 1 and g0 = 1, as expected.
Finally, suppose that g0 ≥ 1 and y0 ≥ 1. Then y˙ = 0 and y(t) = y0. Therefore,
depending on the initial conditions, we can obtain any y∗ > 0 when g∗ = 1, so the
entire critical line is a set of equilibria. 
Numerical Results for the No-DAG System
Since the approximations determined for the degenerate case above are based on
theoretical results, it is important to determine how well they match the calculated
trajectories for the full system. Parameters in this section are not based on the nu-
merical results determined in the short term model as the focus is on representing a
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Figure 4.1: Normal Case: Time Series Plots for System (4.2)
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clear picture of the model dynamics and not on demonstrating an ability to match
data.
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In the cases where the equilibria does not lie on the switching manifold, the
system dynamics evolve as expected (Fig. 4.1). Notice that when glucose infusion
(Gin) is excessive, the glucose is stored as glycogen and cellular levels of glucose
remain around the ideal concentration (gy, 4 in this case). Additionally, in Fig.
4.1 (b), when the glucose infusion is insufficient, glycogen in depleted in order to
maintain cellular glucose at ideal concentrations. Only after glycogen has been filled
or depleted do cellular levels of glucose rise or decline and approach equilibrium.
Hence this system exhibits the expected response in which glycogen storage buffers
the glucose concentration and acts to maintain ideal concentrations of glucose in the
cell.
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Figure 4.2: 3D Phase Portraits
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Trajectories for G*>gy
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For each simulation in Fig. 4.2, random initial conditions are selected and the
simulations are run until equilibrium. The dynamics of the system when G∗ < gy
or G∗ > gy seem to converge onto a stable manifold and move along it toward the
equilibrium point (Fig. 4.2 (a),(b)). However, the degenerate case simulations in
Fig. 4.2 (c) shows the point at which this stable manifold lies wholly in the switching
manifold, and trajectories approach and stick to it tangentially.
The system bifurcates when the levels of glucose infusion and fatty acid infusion
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Figure 4.3: Bifurcation Conditions
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cross a threshold (Fig. 4.3 (a)). When the level of glucose infusion rises, the bifur-
cation point for fatty acid infusion becomes closer to 0. This indicates that higher
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carbohydrate consumption or endogenous glucose production will induce a high glyco-
gen equilibrium. Since fatty acids compete with glucose for metabolism, if fatty acid
infusion is high enough then the system can equilibrate at the high glycogen equilib-
rium even for a lower rate of glucose infusion. The bifurcation point (Fig. 4.3 (b))
as fatty acid infusion increases for some fixed glucose infusion produces a critical line
of equilibria for glycogen. As stated in the previous section, this condition is exactly
when Fin = Fˆin. Only along this critical line can we achieve values for Y
∗ that are
not either empty (Y ∗ = 0) or full (Y ∗ = my).
This critical line is the degenerate case where G∗ = gy. Notably, in the degenerate
case, Fig. 4.2 (c) demonstrates that solutions stick to the critical line and do not drift
toward either Y = 0 or Y = my. Additionally, trajectories that begin with G > gy
close below the plane Y = my approach but never reach my. This behavior is pre-
dicted by (4.5), which further suggests that only trajectories that begin on Y = my
ever reach the equilibrium value Y ∗ = my in the degenerate case.
The time evolution of the trajectories can be seen in Fig. 4.5 with initial glucose
concentrations below (a) and above (b) the critical line. Notice that the fast-slow
estimates for G and Y match closely with the simulated trajectories, but the approx-
imation above (Eqn. 4.5) is more sensitive to deviations of G0 from the critical line.
Figure 4.4 gives a closer inspection of the error induced by the distance between G0
and gy, where it can be seen that a small deviation above gy (a) causes as much error
as larger deviations below gy (b). However, the main result that various initial val-
ues for G0 yield to different equilibria (Y
∗) is supported, and the estimations match
closely to the numerical simulations.
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Figure 4.4: Degenerate Case: Fast-Slow Estimation Error
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Figure 4.5: Degenerate Case: Time Series with Fast-Slow Estimation
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4.0.4 Insulin Resistant Patient - Including DAG
The case we really wish to study is the one with insulin resistance mediated by
DAG accumulation. The previous simple case considered only a healthy individual
without excessive myocellular DAG concentration, on this we reintroduce the dimin-
ished Gin flux via the equation f5(D). The system we examine (4.7) is 4-dimensional
and retains many of the features of the healthy case.
G˙ =
nGin
n+D
− mgpgG
k + pgG+ pfF
−

Pf (G−gy)
(
1− Y
my
)
Cu+(G−gy) , G ≥ gy, Y < my
0, G ≥ gy, Y ≥ my
PrY (G−gy)
Cl+gyY
, G < gy
Y˙ =

Pf (G−gy)
(
1− Y
my
)
Cu+(G−gy) , G ≥ gy, Y < my
0, G ≥ gy, Y ≥ my
PrY (G−gy)
Cl+gyY
, G < gy
(4.7)
F˙ = Fin − mfpfF
k + pgG+ pfF
− dF
D˙ = cdF − µD
Theorem 6 If mg > Gin then system (4.7) has a unique equilibrium, (G
∗, Y ∗, F ∗),
given by
G∗ =
A¯
pg
(k + pfF
∗),
D∗ =
cd
µ
F ∗,
A¯ =
Gin
mg −Gin + mgcdnµ F ∗
.
for a unique F ∗ > 0.
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Case 1: G∗ < gy, Y ∗ = 0
Case 2: G∗ > gy, Y ∗ = my
Case 3: G∗ = gy, Y ∗ ∈ [0,∞)
This system has a discontinuous bifurcation at G∗ = gy.
Proof:
Case 1: G∗ < gy
To begin, we set f3 = 0 and find that
Y ∗ = 0.
Then we look to solve for G∗ in G˙|Y=0 = 0,
G˙|Y=0 = nGin
n+D∗
− mgpgG
∗
k + pgG∗ + pfF ∗
= 0.
Multiply both sides by the denominator on the second term, which can never be 0,
nGin
n+D∗
(k + pgG
∗ + pfF ∗)−mgpgG∗ = 0,
then collect terms on G∗ and move to the RHS
nGin(k + pfF
∗)
n+D∗
= pg
(
mg − nGin
n+D∗
)
G∗
and divide by the coefficient of G∗ to isolate
G∗ =
A¯
pg
(k + pfF
∗)
A¯ =
nGin
n+D∗
mg − nGinn+D∗
=
Gin
mg −Gin + mgn D∗
.
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In order to solve for F ∗, we must first determine D∗, which is simply
D∗ =
cd
µ
F ∗.
Then we plug in G∗ and D∗ to F˙ ∗ = 0
F˙ = Fin − mfpfF
∗
k + Gin
mg−Gin+mgcdnµ F ∗
(k + pfF ∗) + pfF ∗
− dF ∗ = 0.
Simplify the compound fraction
Fin−
mfpf (mg −Gin + mgcdnµ F ∗)F ∗
k(mg −Gin + mgcdnµ F ∗) +Gin(k + pfF ∗) + pfF ∗(mg −Gin + mgcdnµ F ∗)
−dF ∗ = 0,
and collect common terms on the denominator
Fin −
mfpf (mg −Gin + mgcdnµ F ∗)F ∗
mg(k + pfF ∗)(1 + cdnµF
∗)
− dF ∗ = 0.
Next we multiply both sides by the denominator on the second term, which is never
0 valued,
mgFin(k+pfF
∗)(1+
cd
nµ
F ∗)−mfpf (mg−Gin+mgcd
nµ
F ∗)F ∗−dmg(k+pfF ∗)(1+ cd
nµ
F ∗)F ∗ = 0
and expand, collecting common terms on powers of F ∗, and for sake of clarity, multiply the
equation by -1 to obtain,
cd2mgpf
nµ
F ∗3 +mg
(
cd
nµ
Θ + dpf
)
F ∗2 +
(
mgΘ− cdkmgFin
nµ
−mfpfGin
)
F ∗ − kmgFin,
(4.8)
Θ = pf (mf − Fin) + dk.
This cubic polynomial guarantees us at least one positive equilibria because the leading
coefficient is positive and the constant is negative, so it must cross the positive axis. We
consider two cases: Θ > 0 and Θ < 0 in search for additional possible equilibria.
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If we assume Θ > 0, then
Fin < mf +
dk
mf
and the second order coefficient is positive. Then the first order coefficient
mgΘ− cdkmgFin
nµ
−mfpfGin
could be positive or negative depending on parameter choices, however either case provides
a single change in sign. Then Descartes’ rule of sign still suggests a single real positive
equilibrium.
Suppose then that Θ < 0. Then the first order coefficient is negative and the sign of
the second order coefficient does not affect the number of sign changes. Hence, this situa-
tion still yields a single real positive equilibrium. Therefore this cubic polynomial always
presents a single positive equilibrium, which we will call F ∗. The solution of the polynomial
is excluded as it too cumbersome to be useful.
Case 2: G∗ > gy
In this case, we first solve for f3 = 0 and find that Y
∗ = my. Upon substitution into
the other equations, the system is identical to that of case 1. Hence we again have
G∗ =
A¯
pg
(k + pfF
∗)
D∗ =
cdF ∗
µ
A¯ =
Gin
mg −Gin + mgn D∗
where F ∗ is the positive solution to the cubic expression in equation (4.8).
Case 3: G∗ = gy
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Given G∗ = gy, then Y˙ = 0 is automatic and independent of the value of Y ∗. Hence,
when this equilibrium exists, Y ∗ can be any non-negative value. We have D∗ = cdF
∗
µ and
substituting G∗ = gy we get
G∗ =
Gin
pg(mg −Gin + cdmgnµ F ∗)
(k + pfF
∗) = gy,
then
Gin(k + pfF
∗) = gypg(mg −Gin + cdmg
nµ
F ∗),
and solving for F ∗ yields
F ∗(pfGin − cdgymgpg
nµ
) = gypg(mg −Gin)− kGin,
then divide
F ∗ =
gypg − k Ginmg−Gin
pf
Gin
mg−Gin −
cdgymgpg
nµ(mg−Gin)
,
and substituting A = Ginmg−Gin ,
F ∗ =
gypg −Ak
pfA− cdgymgpgnµ(mg−Gin)
.
Notice that this degenerate case has an additional restriction in addition to those imposed
for system (4.2),
pfA >
cdgymgpg
nµ(mg −Gin)
or
Gin >
cd
nµ
· gypg
pf
mg
and combined with the necessary condition for the positivity of the numerator
pggy
pggy + k
mg > Gin >
cd
nµ
· gypg
pf
mg,
implies that the degenerate case can only exist if
1
pggy + k
>
cd
nµ
1
pf
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which can be interpreted as
pf >
cd
nµ
(k + pggy)
implying that the proportion of fatty acids available for metabolism has to be sufficiently
large. Biologically, the implication is that cellular glucose levels can remain at ideal levels
only if the proportion of fatty acids available for oxidations is greater than the average
production and lifespan of DAG times the half-maximal metabolism rate of fatty acids at
glucose equilibrium, reduced by the half saturation constant for DAG mediated insulin re-
sistance. In other words, the proportion of fatty acids available for metabolism must be
greater than the magnitude of effect DAG has on reducing glucose infusion times the con-
centration of fatty acids necessary for half maximal oxidation.
If fatty acid metabolism saturates quickly (i.e. k + pggy is small), if the half saturation
of DAG-induced IR is large (i.e. n is large), or if the production and lifespan of DAG is
small (i.e. cdµ small) then the glucose equilibrium can remain at ideal levels. This indicates
that individuals with efficient fatty acid metabolism or low rates of DAG production can
easily find conditions to maintain glucose at ideal cellular concentrations.
Suppose that these conditions are met, we can substitute the conditions into F˙ and
determine the rate of fatty acid infusion (Fin) required to achieve this equilibrium. Call
this particular critical value F¯in.
F˙ = F¯in −
mfpf
gypg−Ak
pfA− cdgymgpgnµ(mg−Gin)
k + pggy + pf
gypg−Ak
pfA− cdgymgpgnµ(mg−Gin)
− d gypg −Ak
pfA− cdgymgpgnµ(mg−Gin)
= 0
which can be rearranged to
F¯in =
(mg −Gin)(pggy −Ak)
(
mfpf
(
pfA− cdgymgpgnµ(mg−Gin)
)
+
dgymgpg
mg−Gin
(
pf − cdnµ (k + gypg)
))
mgpggy(pfA− cdgymgpgnµ(mg−Gin) )(pf − cdnµ (k + gypg))
.
Notice that F¯in is positive if the conditions for F
∗ > 0 are met for G∗ = gy. Then G∗ = gy
when Fin = F¯in. 
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Suppose we take c = 0, then
F¯in =
(mg −Gin)(pggy −Ak)
(
mfpf (pfA) +
dgymgpg
mg−Gin (pf )
)
mgpggy(pfA)(pf )
.
=
(mg −Gin)(pggy −Ak)(mfpfA+ dmgpggymg−Gin )
mgpggypfA
= Fˆin
So the critical value F¯in agrees with Fˆin when the production of DAG (c) is removed. Then
∂
∂c
F¯in =
(mg −Gin)(pggy −Ak)
gymgpg
(
pfA− cdgymgpgnµ(mg−Gin)
)2 (
pf − cdnµ(k + gypg)
)2
×
[
dmfpf
nµ
(
pfA− cdgymgpg
nµ(mg −Gin)
)2
(k + gypg) +
(dgymgpg)
2
nµ(mg −Gin)2
(
pf − cd
nµ
(k + gypg)
)2]
is always positive when the conditions are met. So the production of DAG increases the
necessary influx of fatty acids to produce the ideal glucose concentration equilibrium for any
given glucose infusion. This result suggests that DAG mediated insulin resistance protects
muscles against elevated concentrations of glucose at the expense of other tissues in the body.
Additionally, if you take c = 0 in the polynomial (4.8) you get
dpfmgF
∗2 + (mgΘ−mfpfGin)F ∗ − kmgFin = 0, (4.9)
Θ = pf (mf − Fin) + dk.
which, if multiplied by (1+A)mg , yields
dpf (1 +A)F
∗2 +
(1 +A)
mg
[mfpf (mg −Gin)−mg(dk − pfFin)]F ∗ − kFin(1 +A) = 0.
and since 1 +A =
mg
mg−Gin , we have
dpf (1 +A)F
∗2 + [mfpf + (dk − pfFin)(1 +A)]F ∗ − kFin(1 +A) = 0,
which is the same quadratic that arises from the system (4.2). Then the addition of DAG
production in system (4.7) doesn’t result in more equilibria, but an altered equilibrium.
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Moreover, if you take the polynomial (4.8) and subtract the quadratic (4.9), then you are
only left with the terms containing c,
cdmg
nµ
F ∗
(
dpfF
∗2 + ΘF ∗ − kFin
)
which is positive for
F ∗ >
−Θ +√Θ2 + 4dkpfFin
2dpf
,
and negative for (F ∗ <).
Let f(F ) be the cubic polynomial (4.8), g(F ) be the quadratic (4.9), F ∗ be the positive
zero such that f(F ∗) = 0, and F¯ be the positive zero such that g(F¯ ) = 0. Put fc(F ) =
f(F )− g(F ), the terms of f(F ) that contain c. Then fc(F ) > 0 implies that f(F ) > g(F ),
hence 0 = f(F ∗) > g(F ∗) implies that the single positive zero of the concave up quadratic
g(F ) has not occurred yet, hence F ∗ < F¯ . On the other hand, if fc(F ) < 0 then F ∗ > F¯ .
Hence the addition of c decreases the equilibrium value for F ∗ if F ∗ > −Θ+
√
Θ2+4dkpfFin
2dpf
,
but increases it if below that condition. It is not clear if the positive zero for (4.8) could
be greater or less than this threshold, as the expression for F ∗ is algebraically intractable.
Understanding the role that DAG production plays on the value of F ∗ is important since
our expressions for G∗ and D∗ both vary as F ∗ does. We will explore this numerically.
Numerical Results for the DAG system
The simulations for the 4-dimensional system mirror the dynamics that we see in the 3
dimensional system. The key feature of the simulations is how glycogen stores help to
maintain a preferable glucose concentration in the cell. However, once the glycogen is de-
pleted or filled to capacity, the cell cannot maintain ideal levels of glucose and the system
hits equilibrium.
Keeping glucose infusion constant, Fig. 4.6 demonstrates the dynamics of the system
when fatty acid infusion is high. The DAG concentration in this case lowers the glucose
83
Figure 4.6: Simulations for System (4.7) with High Fin
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infusion via DAG-mediated insulin resistance, and the steady state concentration of DAG
is high enough that glucose levels can only be maintained at ideal levels until the glycogen
stores are depleted. After glycogen is depleted, glucose concentrations stabilize at a lower
equilibrium. On the other hand, for the same value of Gin, Fig. 4.7 shows that the lower
concentrations of fatty acids and DAG in the cell allows the cell to maintain constant glu-
cose levels until glycogen fills to capacity.
The relationship between F¯in and Gin in Fig. 4.8 demonstrates that as Gin increases,
the necessary influx of fatty acids necessary to maintain ideal concentrations of intramyocel-
lular glucose increases. Moreover, the vertical dashed grey line is the lower bound threshold
for the existence of the degenerate case (i.e. Gin =
cd
nµ · gypgpf mg). Any glucose infusion below
the dashed grey line will result in a glucose equilibrium below the ideal concentration and
a depleted glycogen store for any fatty acid infusion. Notice that this is distinctly differ-
ent than in Fig. 4.3, where there is always some critical value of Fˆinthat would yield the
degenerate case for any small Gin. Hence the addition of DAG mediated insulin resistance
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Figure 4.7: Simulations for System (4.7) with Low Fin
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generates a cutoff for glucose infusion, below which you can never fill glycogen stores.
In order to better understand the relation between DAG production (c) and the value
of the fatty acid equilibrium (F ∗) we look at how F ∗ varies as c is increased away from
0. The plot in Fig. 4.9 demonstrates that the addition of DAG production in fact re-
duces the equilibrium value of F ∗. Furthermore, while we expect DAG to be fraction of
the total byproducts created from IMCL (hence c < 1), we can see that the equilibrium,
F ∗ approaches the value of the expression −Θ+
√
Θ2+4dkpfFin
2dpf
(Fig. 4.9 (b)). This clearly
implies that the terms containing c take over the behavior of (4.8) if we let c get very large.
However, this is not biologically feasible, hence we only expect to see some minor decrease
in fatty acid concentration such as in Fig. 4.9 (b).
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Figure 4.8: Bifurcation Conditions on Fin and Gin
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Figure 4.9: Effect of DAG Production on F ∗
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Chapter 5
DISCUSSION AND FUTURE WORK
5.1 Discussion
Intramyocellular triglyceride, and more generally intramyocellular lipids, play an impor-
tant role in regulating muscular glucose uptake during a state of high fatty acid influx. This
leads to DAG accumulation and glucose transport reduction. The mathematical model pro-
posed is capable of fitting euglycemic-hyperinsulinemic clamp with fatty acid infusion data
with reasonable parameter values. Not only does the model replicate data dynamics, it fits
4 related data sets simultaneously with a single set of parameters. This fact indicates that
the major mechanisms driving the dynamics seen in (Roden et al., 1996) are represented in
this model.
The model’s highly nonlinear nature makes it likely that the parameter set found in our
estimation is not a global minimum, and uncertainty in our parameter choices could have
a large effect on the model’s predictive power. Most importantly, the parameters related
to glucose and fatty acid infusion into the myocytes change the fit quite dramatically, but
those parameters at least have a known feasible range if you have enough information from
the clinical procedure. The parameters that govern DAG production and DAG-mediated IR
are less well understood and not directly measurable, hence the uncertainty in those values
is high. More data is necessary in order to validate the predictive power of this model.
The long term model dynamics demonstrate simple behaviors. Most notably, the glyco-
gen store works as a buffer to maintain cellular levels of glucose at ideal levels, so long as
glycogen is available and not at maximal capacity, the muscle cells are able to maintain a
fairly constant glucose level. However, the relationship between glucose uptake and fatty
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acid infusion suggests certain dietary considerations.
There are four main long term behaviors that our model predicts which may be relevant
in understanding insulin resistance. The first is the condition when glucose uptake and
fatty acids infusion is low. In this case, the low glucose equilibrium is stable, and glycogen
is depleted. Additionally, DAG does not accumulate and insulin resistance is low. Hence
an increase in glucose availability will be utilized and stored as glycogen readily.
The second scenario is low fatty acid availability but high glucose. This situation fills
the glycogen reserve and intracellular glucose concentrations come to rest at a high equilib-
rium. In this case, insulin resistance is not present, however the intracellular environment
is still hostile due to glucotoxicity from the elevated glucose level. Furthermore, the body
responds to situations like these by storing excess glucose as triglycerides in a process called
de novo lipogenesis. This often occurs in the liver, but can be found in muscle cells as well.
This biological response would increase the pool of intracellular lipids, and would act as a
source in addition to passive diffusion from the blood.
The third scenario is interesting, low glucose utilization and high fatty acid availability
puts the system into the low glucose equilibrium and depletes glycogen stores. However,
without competition from glucose, the fatty acids can be readily metabolized for energy.
Additionally, studies on athlete have shown that a high intramyocellular store of triglyc-
erides is not associated with insulin resistance if there is high turn-over, or metabolism. In
the case of athletes, the fatty acid infusion is high, but the proportion and maximal rate
of β-oxidation lowers the proportion of lipids that are converted into secondary byproducts
like DAG. Additionally, this case assumes a low extracellular glucose concentration, so the
DAG-mediated IR actually spares glucose by allowing it to continue circulating until it is
utilized by other tissues such as nervous tissue. This is a rare case where the insulin resis-
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tance may not be detrimental to health.
The final situation is the most common, high glucose availability and high fat availabil-
ity. The elevated extracellular glucose would come from food consumed, and the elevated
fat could be from nutritive sources, or from circulating body fat spilling over from adipose
tissue. This case yields the high glucose equilibrium since the critical fatty acid infusion
value is actually negative, and biologically infeasible. Thus you have the trifecta, elevated
glucose equilibrium, insulin resistance, and a full glycogen store. This case is the most
stressful case as it provides glucotoxicity for the muscles, and the insulin resistant cells
don’t clear glucose from the body, which leads to glucotoxicity for other tissues as well.
The addition of DAG production to the healthy no-DAG model increases the critical
fatty acid infusion level required to see the ideal glucose concentration equilibrium. This re-
sult suggests that insulin resistance, while detrimental to the body as a whole, can actually
be protective for muscles. In other words, insulin resistance in muscles helps keep intramy-
ocellular glucose concentrations lower by reducing the effective influx from the bloodstream.
Now, our model says nothing of the effects of glucotoxicity on the body, but if muscles are
not utilizing the blood glucose then the glucose levels in plasma will remain higher for
longer. However, when fat is present and available for metabolism in the muscle and DAG
production is proportionally higher, then glucose is spared for other tissues by means of mus-
cular insulin resistance. Hence a low carbohydrate, high fat diet induces insulin resistance
and depletes glycogen stores, but energy production from fat oxidation becomes the main
source of energy. We see this exact result in patients on a ketogenic diet (Volek et al., 2015).
However, the other side of the coin implies that intramyocellular lipid availability reduces
the efficiency of the muscles’ glucose utilization. Hence a diet with higher carbohydrate con-
sumption will benefit from a low fatty acid influx into muscles. If the insulin pathway is not
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restricted, then the muscles can efficiently take up and metabolize glucose, clearing it from
the blood and alleviating hyperglycemia. Clinical trials implementing a high carbohydrate,
very low fat diet demonstrated a significant reduction in IMTG and fat oxidation rates
(Coyle et al., 2001), as well as improved insulin action (Barnard et al., 2005). Hence in
either extreme, with low-fat-high-sugar or low-sugar-high-fat, the muscles can operate in a
healthy way and generate adequate energy. It is only the case of excess sugar and fat, which
is likely associated with excess total caloric intake, where we see an insulin resistant and
glycogen replete individual. Moreover, the line (F¯in(Gin)) that separates the low and high
glycogen equilibria follows an inverse monotone relation with a single positive zero. Hence
a healthy balance of glucose and fat availability is only possible up until a maximum calorie
intake.
Mathematically, the switching manifold for the long term system brings up interesting
questions in a field that is not heavily studied. The discontinuous bifurcation that is in-
duced as the bifurcation crosses the switching manifold creates a dense line of equilibria.
However, more work needs to be done in order to prove that the trajectories which approach
the line get stuck and do not slide toward either extremum (the trivial or maximal glycogen
equilibria).
The 3 dimensional model (system (4.2)) demonstrates these mathematically interesting
dynamics, whereas the additional state variables change the conditions necessary for the
degenerate case, but do not significantly alter the qualitative behavior. This similarity is
demonstrated in numerical simulations, as the 4 and 5 dimensional long term systems were
too cumbersome to work with while exploring the bifurcation.
Ultimately, the results suggest that simple relationships between glucose and fatty acid
availability drive the long term system dynamics. More questions arise, however when con-
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sidering general model. As more information comes to light about how the intramyocellular
lipids are utilized and how their byproducts affect insulin resistance, this dissertation acts
as a base camp from which new model formulations can be constructed and studied.
5.2 Future Work
The model uses naive assumptions about the functional forms of molecular interac-
tions. Therefore this model can be improved by choosing more accurate interaction terms.
Specifically, the production of DAG is linearly proportional to IMCL concentration, and
nonlinear saturable functions would likely represent the biological mechanisms more realis-
tically. Another obvious improvement would be the reduction of glucose infusion by DAG
concentration. In the cell, DAG does not directly affect GluT4 nor does blocking the IRS
activity immediately down regulate glucose transport. Thus a distributed delay for insulin
action inhibition would be the most realistic. However, while the long term behaviors may
be similar, this addition would likely affect transient dynamics the most.
The main molecule responsible for down regulating insulin activity in euglycemic hyper-
insulinemic clamps with fatty acid infusion is DAG. This is due to the fatty acid infusion
being unsaturated, and some studies have shown that fatty acid induced insulin resistance
occurs without an increase in DAG, but an increase in ceramides. Ceramides can be in-
creased via infusion of saturated fatty acids, but fewer trials of this form have been per-
formed. A comparison between data from typical fatty acid infusions and saturated fatty
acid infusions would give insight into fundamental differences between the dynamics and
would motivate a more realistic long term dynamics analysis of the model. Additionally, it
is possible that DAG and ceramides work together or against each other in some ways that
may inspire attaching additional model variables.
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This model needs to be tested against more data to determine how robust the chosen
parameters are. Given the already complex non-linear nature of the model, the found pa-
rameters likely account for one of many parameter sets that locally minimize the difference
between simulation and observation. Thus a more thorough vetting of the parameter es-
timation is needed before this model will be useful in a clinical setting. Additionally, this
model can be improved as more biological research elucidates the in vivo enzyme interaction
dynamics. Parameter estimation will shed light on which model choices make the biggest
difference in predictive accuracy. Hence it is important to try different model functions that
demonstrate the same qualitative behavior and test them against each other to determine
which assumptions best fit the clinical data.
Additionally, the measure of muscular insulin resistance determined by the concentra-
tion of DAG provides a novel measure of insulin sensitivity. With the multitude of other
insulin sensitivity indices, it would be interesting to determine the differences that this
model provides. Moreover, the muscular insulin resistance likely only accounts for a subset
of insulin resistance in a diabetic patient, and this new metric may help shed light on what
role muscular insulin resistance plays in whole body insulin resistance.
Furthermore, the long term model dynamics need to be studied in more detail. For
instance, if there is an enzyme dysfunction (or knockout) that disallows the normal cellular
switching from storing to utilizing glycogen, does the system exhibit other types of bifurca-
tions? Perhaps we can discover some other typical bifurcations in the system. Additionally,
the switching mechanisms are not, in reality, completely on or off. Hence, some delayed
switching time or transition could clarify the cellular dynamics. The results of stability
we have already discovered could be strengthened by demonstrating global stability with a
Lyaponov function or Dulac critereon tests.
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Lastly, this model describes a single clinical protocol that is not only expensive, but
short term in scale. The larger application of such a model would be in discovering if these
dynamics are a cause of, or result of, chronic insulin resistance. Since the model assumes
a constant inflow of glucose and fatty acids, it is currently not guaranteed to be bounded
depending on parameter and function choices. Therefore, we need to add self regulation to
the system in addition to non-autonomous nutrient infusion rates that depend on external
stimuli such as glucose and insulin concentration. Fortunately, glucose-insulin dynamics
have been well studied and models of this variety are being used for other predictive appli-
cation such as closed loop control insulin injection algorithms for type 1 diabetics.
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